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ABSTRACT  
Aims: 
End stage renal disease (ESRD) patients have an excess cardiovascular 
risk, above that predicted by traditional risk factor models. Despite the 
advances in both Cardiovascular disease (CVD) management and renal 
replacement therapy (RRT), there still is a major burden of 
cardiovascular mortality and morbidity in the chronic kidney disease 
(CKD) population. Declining renal function itself represents a 
continuum of cardiovascular risk and in those individuals who survive 
to reach ESRD, the risk of suffering a cardiac event is uncomfortably 
and unacceptably high. Pro-thrombotic status may contribute to this 
increased risk. Global thrombotic status assessment, including 
measurement of occlusion time (OT) the time taken to form an 
occlusive platelet rich thrombus and thrombolytic status (time taken to 
lyse such thrombus) as assessed by measuring Lysis Time (LT), may 
identify vulnerable patients. The aim of this study was to assess 
overall thrombotic status in ESRD and relate this to cardiovascular and 
peripheral thrombotic risk. Small sub studies were also planned to 
establish the effect of RRT modality on the thrombotic status. 
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Methods and results 
Thrombotic and thrombolytic status of ESRD patients (n = 216) on 
haemodialysis and 100 healthy volunteers was assessed using the 
Global Thrombosis Test (GTT). This novel, near-patient test measures 
the time required (OT) to form and time required to lyse (lysis time, 
LT) an occlusive platelet thrombus. Patients were followed-up for a 
minimum 1 year for major adverse cardiovascular events (MACE; 
composite of cardiovascular death, non-fatal MI, or stroke). Peripheral 
arterial or arterio-venous fistula thrombosis was a secondary endpoint. 
The 100 healthy volunteers did not have any renal impairment, and 
were not taking any medications. There were 55 males and 45 females, 
and mean age was 38±11 years (range 22-76, IQR 11). OT was 
normally distributed with mean OT 378 sec (200-550 sec). LT 
demonstrated a skewed distribution ranging from 457 to 2934 sec. A 
median of 1053 sec (600-2000s) was established for LT.  OT was 
prolonged (491±177 vs. 378±96 s, P<0.001) and endogenous 
thrombolysis was impaired (LT median 1820 vs.1053 s, P< 0.001) in 
ESRD compared with normal subjects. LT≥3000 s occurred in 42% of 
ESRD patients, and none of the controls. Impaired endogenous 
thrombolysis (LT≥3000 s) was strongly associated MACE (HR-4.25, 
95% CI 1.58– 11.46, p=0.004), non-fatal MI and stroke (HR-14.28, 
95% CI 1.86–109.90, p=0.01), and peripheral thrombosis (HR -9.08, 
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95% CI 2.08–39.75, p=0.003). No association was found between OT 
and MACE. 
Small sub studies were performed on patients receiving peritoneal 
dialysis (PD) and also post renal transplant recipients to compare the 
thrombotic status assessed by GTT in patients with different modalities 
of RRT. These patients did not have any clinical follow-up. The global 
thrombotic status of renal transplant recipients or PD patients was not 
different to that of the HD patients suggesting that the modality of 
RRT does not alter the thrombotic status in ESRD. 
 
Conclusion:  
Impaired endogenous thrombolysis, as measured by using the near 
patient, bed-side novel test, is a novel risk factor in ESRD. It is 
strongly associated with cardiovascular events. Further studies are 
required to confirm the role of impaired endogenous thrombolysis as 
an independent risk factor for CVD in CKD patients.   
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Thesis Outline 
 
 
This thesis has been divided into 8 chapters. In the first chapter I have 
discussed the burden of CKD and the magnitude of CVD in ESRD 
patients and reviewed the possible risk factors implicated in this. I 
have then discussed the mechanism of thrombotic events in general 
and the possible explanation of the differences found in ESRD 
compared to patients with normal renal function.  I have then 
reviewed the available platelet function tests, drawbacks in currently 
available tests and thus the need for a new test. 
In chapter 2 and 3 I have outlined the hypothesis, aims and 
methodology used to perform this study. In this chapter I have also 
detailed the main test used to perform the study –GTT. It also lists the 
reasons for choosing peripheral venous sample as compared to fistula 
sample in HD patients for GTT analysis which is then further discussed 
in detail as a sub-study in chapter 4 
Chapter 5 outlines the demographics of the main study group (HD 
patients) and the OT and LT values observed in the HD group. This 
showed significantly prolonged LT in HD population compared to the 
healthy volunteers. The effects of demographic profile, medical co-
morbidities and medications on the OT and LT of HD patients are then 
studied in this chapter. Following this the relationship between OT and 
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LT and the study endpoints is established. This showed that 
significantly prolonged LT (>3000s) was an independent risk factors in 
this study group for MACE and secondary end-points. 
Chapter 6 and 7 are establishes the OT and LT in small groups of 
patients receiving PD or post renal transplant and then a comparison is 
made with the main study population. 
Chapter 8 is a general discussion about the methodology, rationale of 
the study, possible explanations of the results and limitations of the 
study. It also briefly highlights possible future work.  
In the end are the references and the appendices which include the 
ethical approval letters, data collection sheets, patient and GP 
information sheets. 
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1.1 Introduction  
This chapter has two parts. In the first part of this chapter I will 
discuss the burden of chronic kidney disease (CKD) and the magnitude 
of (CVD) in end stage renal disease (ESRD) patients and review the 
possible risk factors implicated in this. I will then go on to explain the 
mechanism of thrombotic events in general and the possible 
explanation of the differences found in ESRD compared to patients 
with normal renal function.  In the second part of this chapter I will 
review the available literature on the platelet function testing, 
drawbacks in currently available tests and thus the need for a new test. 
 
1.1.1 CKD prevalence 
The prevalence of CKD is high and rising, affecting 13% of the 
population in the United States in 1999–2004 as compared with 11% 
in 1988–1994, according to data from the National Health and 
Nutrition Examination Survey (1). More or less similar prevalence 
estimates have been reported in Australia (2), Norway (3) and the 
United Kingdom (4).  In a UK-based cross-sectional study, the overall 
prevalence of CKD estimated Glomerular Filtration Rate (eGFR) <60 
ml/min/1.73 m2) in a population of older people aged 75 years or 
more was 56.1% (95% CI: 55.3–57.0). The prevalence of eGFR less 
than 45 and 30 ml/min/1.73 m2 was 17.7% (95% CI: 17.1–18.4) and 
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2.7% (95% CI: 2.4–2.9), respectively (5). The prevalence may be 
even higher among institutionalized older people, with 82% of a 
residential home population in the UK having a GFR equivalent to 
stage 3 CKD or worse, and 40% with stage 3B CKD or worse (6).  
CKD typically evolves over many years, with a long latent period when 
the disease is clinically silent and therefore diagnosis, evaluation and 
treatment is based mainly on biomarkers that assess kidney function. 
In 2002, the National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative (NKF KDOQI) instituted new guidelines that 
established a novel CKD staging paradigm. In this model, CKD was 
categorized into five stages based on eGFR range: I, II III IV and V (7) 
eGFR more than 90 mL/min per 1·73 m² (stage 1), 60–89 mL/min per 
1·73 m² (stage 2), 30–59 mL/min per 1·73 m² (stage 3), 15–29 
mL/min per 1·73 m² (stage 4), and less than 15 mL/min per 1·73 m² 
(stage 5) 
Some CKD patients are able to maintain stable, albeit diminished 
glomerular filtration rates over several years, the so-called “non-
progressors” or “asymptomatic” CKD patients, whereas, other CKD 
patients, for often unclear reasons, have an apparent enhanced 
propensity to progressively lose GFR over time, the so-called 
“progressors” or “symptomatic” CKD (8). The natural history of 
progression in certain conditions such as polycystic kidney disease and 
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diabetic nephropathy is well documented with these diseases, often 
following a predictable linear decline. However, much less is known 
about the rate and nature of progression in general population-based 
cohorts of CKD patients, particularly in the elderly. Studies have 
consistently shown that in patients with CKD, death is far more 
common than progression of kidney disease (9). 
Keith et al. (10) identified 27,998 patients who had eGFR <90 
ml/min/1.73 m2 measured on at least 2 occasions separated by 90 
days. Subjects were followed-up for 66 months or until death or 
initiation of renal replacement therapy (RRT). Death was found to be 
significantly more common at each stage of CKD compared with the 
frequency of RRT: 19.5% in stage 2, 24.3% in stage 3 and 45.7% in 
stage 4 died compared with rates of RRT of 1.1, 1.3 and 19.9% in 
each stage, respectively. Two other population-based studies have also 
demonstrated that the risk of death far exceed the risk of progression 
to RRT. Drey et al. (11) found that only 4% of those with creatinine 
>150 µmol/l progressed to RRT compared with 69% who died during 
the 5.5-year follow-up. Foley et al. (12) examined 5% of the Medicare 
population and found that the rate of death per 100 patient-years were 
significantly higher than the risk of progression to RRT in CKD patients 
with and without diabetes. The risk of mortality, principally from CVD, 
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in older people with CKD outweighs the risk of progression to ESRD 
(13).  
Patients with ESRD consume a disproportionate amount of health care 
resources. However, despite the magnitude of the resources 
committed to the treatment of ESRD and the substantial 
improvements in the quality of dialysis therapy, these patients 
continue to experience significant mortality and morbidity, and a 
reduced quality of life. 
The modalities of RRT available for the treatment of (ESRD) include 
renal transplantation, haemodialysis (HD), and peritoneal dialysis (PD). 
HD is subdivided into centre HD, the most commonly used modality, 
and home HD. PD comprises both continuous ambulatory PD (CAPD), 
and continuous cycling PD (CCPD), in addition to a small subgroup of 
other forms of PD. Renal transplantation may be from a living donor 
(either a blood relative or other unrelated donor) or a cadaveric donor. 
During the course of their treatment for ESRD, patients may switch a 
number of times between different modalities of renal replacement 
therapy. For example, a given patient might move from CAPD to 
transplantation and, after transplant failure, to haemodialysis and 
perhaps to a second transplant. 
According to the United States renal data system 2014 annual report 
(14) the use of PD and pre-emptive kidney transplant were relatively 
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more common in younger patients.  The use of home dialysis in the 
USA has increased significantly since 2002 and was 35% higher in 
2012 (c.f 2002). The majority of patients receiving home dialysis 
(95%) were receiving PD. 
The numbers of incident case using various modalities of RRT in US in 
the year 2012 based on age, race, ethnicity, sex and aetiology of 
ESRD is shown in the table 1.1 adapted from the  USRDS annual 
report. 
  
 
Table 1.1 
Table 1.1 : Number and percentage of incident cases of HD, PD and transplantation (Tx) by age, sex, 
race, ethnicity, and primary ESRD diagnosis, in the U.S. population, 2012  
 
                                                    HD                                     PD                       Tx  
            N          %      N                     %                     N                   % 
                                              
Age  
0-19  
506  0.5  349  3.8  245  8.7  
20-44  
10,375  10.5  1,650  18.0  661  23.6  
45-64  
38,268  38.7  3,952  43.1  1,355  48.3  
65-74  
24,528  24.8  1,900  20.7  485  17.3  
75+  
25,277  25.5  1,324  14.4  57  2.0 
  
Sex 
 
Male  56,847  57.4  5,197  56.6  1,612  57.5  
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Female  42,107  42.6  3,978  43.4  1,191  42.5  
 
Race  
 
White  65,430  66.1  6,415  69.9  2,288  81.6  
Black/ 
African Am  
28,659  29.0  2,137  23.3  292  10.4  
Native 
American  
1,139  1.2  87  0.9  29  1.0  
Asian  3,726  3.8  536  5.8  194  6.9 
  
Ethnicity  
 
Hispanic  13,702  13.8  1,251  13.6  420  15.0  
Non- 
Hispanic  
85,252  86.2  7,924  86.4  2,383  85.0 
  
       
Primary cause of ESRD  
 
Diabetes  43,922  44.4  3,783  41.2  441  15.7  
Hyperten-
sion  
29,111  29.4  2,373  25.9  257  9.2  
Glomerulo-
nephritis  
6,889  7.0  1,387  15.1  553  19.7  
Cystic 
kidney  
1,551  1.6  476  5.2  429  15.3  
Other 
urologic  
410  0.4  61  0.7  54  1.9  
Other Cause  10,762  10.9  682  7.4  501  17.9  
Unknown/ 
missing  
6,309  6.4  413  4.5  568  20.3  
All  98,954  100.0  9,175  100.0  2,803  100.0  
ADAPTED FROM USRDDS DATABASE (www.usrds.org/2014) 
Data Source: Special analyses, USRDS ESRD Database. Abbreviation: African Am, African American; ESRD, end-stage 
renal disease. 
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In comparison, the UK renal registry 17th annual report stated that 
there were 56,940 adult patients receiving RRT in the UK on 31st 
December 2013, an absolute increase of 4.0% from 2012. The actual 
number of patients increased 1.2% for HD, 7.1% for those with a 
functioning transplant but decreased 3.3% for PD. The UK adult 
prevalence of RRT was 888 per million population (pmp) compared to 
523 pmp. in the year 2000. The number of patients receiving home HD 
increased by 3% from 1,080 patients in 2012 to 1,113 patients in 
2013. The median age of these patients was 58.4 years (HD 66.9 
years, PD 63.7 years, transplant 52.8 years). In 2000 the median age 
was 55 years (HD 63 years, PD 58 years, transplant 48 years). The 
percentage of RRT patients aged greater than 70 years old increased 
from 19.2% in 2000 to 25% in 2013. For all ages, the prevalence rate 
in men exceeded that in women, peaking in age group 75–79 years at 
3,010 p.m.p. in men and for women at 1,560 p.m.p.  
 
Unlike the US, the most common identifiable renal diagnosis was 
glomerulonephritis (19.0%), followed by uncertain aetiology (16.0%) 
and diabetes (15.9%). Transplantation continued to be the most 
common treatment modality (52%), HD was used in 41.6% and PD in 
6.4% of RRT patients. Prevalence rates in patients aged > 85 years 
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continued to increase between 2012 and 2013 (983 age related pmp 
to 1,020 age related pmp). 
In 2013, 21.1% of the prevalent UK RRT populations (with ethnicity 
assigned) were from ethnic minorities compared to 14.9% in 2007. 
The UK numbers are much smaller than those from the US but are 
comparable to northern European countries according to the UKRDS 
report. 
 
1.1.2 Cardiovascular risk in CKD 
CKD affects around 10–13% of the general population, with only a 
small proportion of these patients exhibiting ESRD, either on dialysis 
or awaiting renal transplantation (1). It is well documented that CKD 
patients have an extremely high risk of developing CVD compared with 
the general population, so much so that in the early stages of CKD 
patients are more likely to develop CVD than they are to progress to 
ESRD. 
A number of studies in the past have demonstrated that as eGFR falls, 
the incidence of CVD increases, independent of associated risk factors 
(15) Go et al. investigated the association between GFR, CVD and 
death in 1,120,295 adults. On multivariate analysis, the adjusted 
hazard ratio for CVD was 1.4 with an estimated GFR of 45–59 
ml/min/1.73 m2 (95% CI, 1.1–1.2) compared with 3.4 (95% CI, 3.1–
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3.8) with an estimated GFR of < 15 ml/min/1.73 m2. Similar findings 
have been reproduced in other large studies and few of these are 
summarized in the table 1.2. 
 
Table1.2*: Studies investigating the association between eGFR and CVD 
 Table modified and adapted from (16).  
Study Outcome 
Number of 
participants 
Comparison 
 
Result (CI; p-value)  
Go et al.  
Any 
cardiovascular 
events 
1,120,290 
eGFR 45–59 vs. > 60 ml/min/1.73 m2 
eGFR 30–44 vs. > 60 ml/min/1.73 m2 
eGFR 15–29  vs. > 60 ml/min/1.73 m2 
eGFR < 15 vs. > 60 ml/min/1.73 m2 
 
 
 
HR 1.4 (CI 1.4–1.5) 
HR 2.0 (CI 1.9–2.1) 
HR 2.8 (CI 2.6–2.9) 
HR 3.4 (CI 3.1–3.8) 
 
 
 
      
Muntner et 
al. * 
Coronary heart 
disease 
14,856 eGFR 15–59 vs. > 90 ml/min/1.73 m2  RR 4.27 (CI 2.09–8.71 p < 0.001)  
       
      
 
      
Manjunath et 
al. ** 
Atherosclerotic 
cardiovascular 
disease 
15,350 eGFR 15–59 vs. 90–150 ml/min/1.73 m2  HR 1.38 (CI 1.02–1.87 p = 0.038)  
       
       
Manjunath et 
al. ** 
Atherosclerotic 
cardiovascular 
disease 
15,350 Every 10 unit reduction in eGFR  HR 1.05 (CI 1.02–1.09 p = 0.006) 
 
      
Manjunath et 
al. ** 
Cardiovascular 
disease 
5135 eGFR 15–59 vs. 90–150 ml/min/1.73 m2  HR 1.31 (CI 1.06–1.62 p = 0.013)  
       
       
Manjunath et 
al. ** 
Cardiovascular 
disease 
5135 Every 10 unit reduction in eGFR  HR 1.05 (CI 1.02–1.09 p = 0.005)  
       
       
 
CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; NIDDM, none insulin dependent diabetes 
mellitus. 
* (17) 
** (18) 
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As early as 1970s it was recognized that there is high burden of 
cardiovascular disease in HD patients (19) Presence of 
angiographically significant coronary artery disease ranges from 25% 
in young non-diabetic HD patients to 85% in older, diabetics with 
ESRD (20) When compared to patients without CKD who undergo 
evaluation for coronary artery disease (CAD), those with ESRD have 
substantially more numerous and severe coronary artery lesions, as 
well as more severe left ventricular dysfunction (21,22) 
 
The 5-year survival of men > 64 year old starting dialysis is worse 
than that of men with colon cancer and prostate cancer (*). The 5-
year survival of women >64 year old starting dialysis is worse than 
that of women with breast cancer and colon cancer (*). (* = U.S. Renal Data 
System: USRDS 1998 Annual Data Report, National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases, Bethesda, MD, April 1998).  
CVD accounts for 40%-50% of deaths in dialysis populations (8).  
Overall, the risk of cardiac mortality is 10 to 20-fold greater in dialysis 
patients than in age and sex-matched controls without CKD.  
 
Despite this, dialysis patients often undergo fewer investigations and 
invasive procedures for CVD, and are prescribed fewer medications for 
these conditions compared with age-matched non-ESRD patients. 
These discrepancies can be explained by the paucity of large trials for 
  
[ S u m e e t  S h a r m a ]  
 
Page 31 
evidence-based treatment strategies in this population, but there is 
concern that this attitude may be impacting on the medical care of 
these patients. 
 
Recently, Roberts et al used registry data to compare age- and era-
specific CVD mortality rates in Australian dialysis patients with rates in 
the Australian general population. The encouraging finding of this 
study is that CVD mortality rates have decreased, in this population, 
over time in both dialysis patients and the general population. The 
concerning finding was that the relative risk of CVD mortality in 
dialysis patients compared with the general population increased. In 
addition, statistical analyses confirmed an interaction between era and 
dialysis status with CVD mortality, indicating significantly higher 
relative risk for dialysis patients in more recent eras (23).  On the 
basis of these observations the authors concluded that despite 
decreasing cardiovascular mortality rates in some dialysis patients, the 
excess cardiovascular risk compared with the general population is 
increasing (24). 
 
The interpretation of this comparison may or may not be extrapolated 
to other populations and certainly has limitations. However it does 
highlight that despite the advances in both CVD management and RRT, 
there still is a major burden of cardiovascular mortality and morbidity 
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in the CKD population. Declining renal function itself represents a 
continuum of cardiovascular risk and in those individuals who survive 
to reach ESRD, the risk of suffering a cardiac event is uncomfortably 
and unacceptably high. It also raises the question of why the rates of 
CVD in dialysis patients are not decreasing at the same rate as in the 
general population. 
 
1.1.3 Risk factors of CVD in CKD 
Although atherosclerosis on its own is predominantly a clinically silent 
process, its consequences and presentations can be catastrophic, and 
in the vast majority of patients may even be the first presentation of 
the disease process. Clinical presentations of atherosclerosis include 
ischemic heart disease, namely, angina, myocardial infarction, and 
sudden cardiac death, which is common in CKD, and cerebrovascular 
disease, peripheral vascular disease, or heart failure. The 
cardiovascular burden in dialysis patients now is recognized to include 
not only accelerated atherosclerosis, but also arteriosclerosis with stiff 
and noncompliant arteries, as well as a high prevalence of 
cardiomyopathy. Thus in practice, it is seen that, although the risk of 
myocardial infarction is increased in patients on dialysis, other 
cardiovascular events, such as sudden cardiac death and heart failure 
are also common in this cohort (25). 
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1.1.4 Traditional Risk Factors 
Most of the traditional CVD risk factors (as defined in the Framingham 
population), such as older age, diabetes mellitus, systolic hypertension 
and high low-density lipoprotein (LDL) cholesterol, are highly prevalent 
in CKD. However, the relationship between these risk factors and 
cardiovascular events in people with kidney disease often differs from 
that in the general population and does not explain the increased risk. 
It is also true that intervening on these traditional risk factors, such as 
lipid lowering with statin therapy have not shown any major benefit of 
cardiovascular event reduction in this population. 
 
Traditional risk factors for CVD and mortality in the general population 
such as body mass, serum cholesterol, and blood pressure are also 
found to relate to outcome in patients receiving maintenance dialysis, 
but often in an opposite direction. Obesity, hypercholesterolemia, and 
hypertension appear to have protective features that may be 
associated with a greater survival among dialysis patients. These 
findings are in contrast to the well-known association between over-
nutrition and poor outcome in the general population. The association 
between under-nutrition and adverse cardiovascular outcome in 
dialysis patients, which appears to contrast to that seen in non-ESRD 
individuals, has been referred to as "reverse epidemiology." The 
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etiology of this inverse association is not clear. Several possible causes 
are hypothesized including survival bias (only a small number of 
patients with CKD survive long enough to reach ESRD, and the 
presence of the "malnutrition-inflammation complex syndrome" (MICS) 
in dialysis patients (26). Both protein-energy malnutrition (PEM) and 
inflammation or a combination of these two, are much more common 
in dialysis patients than in the general population. The degree to which 
PEM in dialysis patients is caused by inflammation is not clear. Some 
studies suggest that PEM and inflammation each independently 
contribute to hypoalbuminemia and subsequently increase morbidity 
and mortality. Since both PEM and inflammation are strongly 
associated with each other and can change many nutritional measures 
in the same direction, and because the relative contributions of 
measures of these two conditions to each other and to outcomes in 
dialysis patients are not yet well defined, MICS has been suggested to 
denote the important contribution of both of these conditions to ESRD 
outcome (27). 
 
The possible causes of MICS include comorbid illnesses, oxidative and 
carbonyl stress, nutrient loss through dialysis, anorexia and a low 
nutrient intake, uremic toxins, a decreased clearance of the 
inflammatory cytokines, a volume overload, and dialysis-related 
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factors. Many elements of MICS, such as a low weight-for-height, 
hypocholesterolaemia, or hypocreatininaemia, are the known risk 
factors of a poor outcome in dialysis patients (28). Because MICS leads 
to a low body mass index, hypocholesterolaemia, hypocreatininaemia 
and hypohomocysteinaemia, a “reverse epidemiology” of the 
cardiovascular risks has been seen in the dialysis patients. 
 
The AURORA trial, was a large international, multicenter, randomized, 
double-blind, prospective trial involving 2776 patients, 50 to 80 years 
of age, who had been undergoing maintenance HD for at least 3 
months. Patients were randomly assigned to receive rosuvastatin, 10 
mg daily, or placebo. The primary end point was the time to a major 
cardiovascular event, defined as a nonfatal myocardial infarction, 
nonfatal stroke, or death from cardiovascular causes (29). In this trial, 
the statin therapy failed to achieve any benefit on the primary 
outcome or its subsets individually, despite achieving a mean 43% 
reduction in the LDL cholesterol level at 3 months. 
 
Similar findings were seen in the 4D study, where 1225 patients with 
type 2 diabetes undergoing maintenance HD received either 
atorvastatin at a dose of 20 mg or placebo. Although the median LDL 
cholesterol level was reduced by 42% with atorvastatin, there was no 
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significant reduction in the composite primary cardiovascular end point 
(30). The lack of benefit of statin therapy in the 4D and AURORA 
studies suggests that CVD risk in patients undergoing HD differs from 
that in other patients. 
The much larger, more recent SHARP study, which included nearly 
10,000 patients with CKD (of whom 3,023 were on maintenance 
dialysis therapy), reported that allocation to simvastatin plus ezetimibe 
achieved a 17% reduction in major atherosclerotic events compared to 
placebo. However, the majority of patients in SHARP were not on 
dialysis and analysis of the subgroup of patients on HD did not show a 
benefit of lipid-lowering therapy (31). Thus for prevention of CVD, 
there is strong clinical evidence supporting the benefit of using statins 
in the early stages of CKD, but there is no clear advantage to their use 
in dialysis patients, a particularly high risk population. 
 
Similarly, blood pressure lowering in CKD patients has not shown any 
major impact on CVD in these patients. The “U shaped” relationship 
between hypertension and mortality is more difficult to explain, not 
least because of the difficulty in defining hypertension in this 
population as there is tremendous variation in BP throughout the 
dialysis cycle making it difficult to establish which BP is most important. 
Also the high prevalence of cardiac dysfunction may account for the 
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increased mortality at low-normal levels of BPThere have been a 
number studies which have indicated that, similar to the risk seen in 
the general population, high systolic or diastolic blood pressure (BP) is 
associated with an increased risk of death in dialysis patients (32). A 
number of large epidemiological studies have paradoxically indicated 
inverse (33) or U-shaped (34) associations between BP and mortality 
in dialysis patients. It has been argued that discrepancies in these 
studies including the so-called “reverse epidemiology” of BP (or 
hypertension paradox) are related to differences in various clinical 
characteristics including comorbid conditions of the studied patient 
populations (35). 
Agents acting via the renin angiotensin system (RAS), including 
angiotensin-converting enzyme (ACE) inhibitors and angiotensin 
receptor blockers (ARBs), are often recommended as first-line 
treatment on the basis of RCTs demonstrating a reduction in renal 
events (for e.g. kidney failure or doubling serum creatinine) in patients 
who have proteinuria, either with (36, 37) or without diabetes 
(Angiotensin-Converting Enzyme Inhibition in Progressive Renal 
Insufficiency (AIPRD) study (38), Ramipril Efficacy in Nephropathy 
study(REIN); (39, 40), or advanced CKD(SCr >3 mg/dl) (41).  
 
Most of the blood pressure lowering trials are driven by renal outcomes 
and the evidence for cardiovascular outcomes is based mainly on sub 
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group analysis of large trials studying ACE–inhibitors, such as the 
ADVANCE (42), PROGRESS (43), HOPE (44), EUROPA (45) studies and 
PEACE STUDY (46).  
 
A post hoc analysis of the ALLHAT study demonstrated that lisinopril 
was not superior to chlorthalidone or amlodipine in preventing 
coronary heart disease, stroke, or combined CVD in patients with 
estimated GFR<60 ml/min/1.73 m2 and chlorthalidone was superior to 
both for preventing heart failure, independent of renal function (47).  
Thus far, despite the increased risk of death and cardiovascular events 
in individuals undergoing dialysis there is no consensus about the 
treatments proven to reduce cardiovascular outcomes, as one would 
expect, by modifying the so-called traditional risk factors. 
 
1.1.5 Novel or non-traditional risk factors 
Due to the discrepancy in the outcomes and burden of traditional risk 
factors in end stage renal disease, the search for novel or non-
traditional risk factors that may be involved in the pathogenesis of 
CVD in ESRD has been an area of intense ongoing research. 
Interventions such as dialysis prescription modification (48), 
homocysteine lowering, (49) mineral metabolism modification (50, 51, 
52) and haemoglobin normalization (53) have been assessed in 
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randomized trials and systematic reviews, but there is no clear 
evidence to show that any of these approaches except possibly more 
frequent dialysis (54) reduces the risk of death or major cardiovascular 
events.  
 
1.1.6 Atherosclerosis in ESRD 
The metabolic environment that results from renal dysfunction appears 
to accelerate the atherosclerotic process by decades in patients with 
ESRD. Atherosclerotic disease may not follow identical pathways in 
people with ESRD compared with those with normal renal function, 
and indeed may be accelerated (55). It has been shown in studies with 
CT calcium scoring that coronary artery calcification occurs more 
frequently in young adults with end-stage renal disease than in either 
normal subjects of the same age and sex or older adults with normal 
renal function (56, 57). 
 
The accelerated atherosclerotic process of ESRD may involve several 
inter-related processes, such as oxidative stress, endothelial 
dysfunction and vascular calciﬁcation, in a milieu of constant low-grade 
inﬂammation (58). Indeed, recent evidence suggests that the uremic 
milieu may affect both the quality and quantity of the atherosclerotic 
plaques. Schwarz et al (59) have shown that coronary plaques in 
uremic patients are characterized by increased media thickness, 
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inﬁltration and activation of macrophages and marked calciﬁcation. 
Importantly, the striking difference compared with non-renal controls 
did not concern the size but rather the composition of the plaque. Thus, 
it could be postulated that heavily calciﬁed and inﬂamed plaques 
contribute to the excessive cardiovascular risk in ESRD patients. 
The inﬂammation in ESRD is multifactorial and, while it may reﬂect 
underlying CVD, an acute-phase reaction may also be a direct cause of 
vascular injury via several pathogenic mechanisms. Available data 
suggest that pro-inﬂammatory cytokines play a central role in the 
genesis of both malnutrition and CVD in ESRD (60). Thus, it could be 
speculated that suppression of the vicious cycle of malnutrition, 
inﬂammation and atherosclerosis (MIA syndrome) would improve 
survival in dialysis patients.  
 
1.1.7 Platelets in athero-thrombosis 
Platelets are cells which circulate in blood. They are of pivotal 
importance in blood clot formation, affecting thrombosis and 
haemostasis. By rapidly altering the activation and expression of 
surface receptors, platelets are able to quickly undergo structural and 
phenotypic changes in response to stimulation, such as collagen 
exposure from beneath injured vascular endothelium. The main trigger 
for the formation of a haemostatic thrombus is the loss of the 
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endothelial cell barrier between extracellular matrix components and 
flowing blood. This exposes platelets to the thrombogenic components 
of the sub-endothelium. Among the main components exposed are 
proteoglycans, collagen type IV, entactin, laminin, fibulin and von 
Willebrand factor (vWF) (61). 
 
 In response to stimulation platelets become adhesive, aggregate to 
form a thrombus, and release a variety of mediators affecting 
coagulation, inflammation, and chemotaxis at the site of injury. 
Platelet adhesion under conditions of high shear stress, as occurs in 
stenotic atherosclerotic arteries, is central to the development of 
arterial thrombosis; therefore, platelet activation and adhesion must 
be prevented in order to maintain blood fluidity and to prevent 
thrombotic or haemorrhagic complications. The main inducers of 
platelet activation are collagen, vWF, alpha-thrombin, adenosine 
diphosphate (ADP) and thromboxane A2. ADP is essential to the 
platelet response because after its secretion from the platelet dense 
granules where it is stored, it amplifies the responses induced by other 
agonists. 
Formation of the platelet plug in response to vascular injury can be 
thought of as occurring in three stages: initiation, extension, and 
perpetuation (Fig1.1) (62).  
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Figure 1.1 Stages in platelet plug formation. A: Prior to vascular injury, platelet 
activation is prevented by inhibitory factors that include PGI2 and NO released from 
endothelial cells, the presence of CD39 on the surface of endothelial cells, and the 
inability of normal plasma VWF to bind spontaneously to the platelet surface. B: The 
development of the platelet plug can be initiated by the exposure of collagen and 
VWF in the vessel wall, and by the local generation of thrombin, a process that 
occurs more rapidly on the surface of activated platelets. C: Rolling platelets adhere 
and spread on the collagen matrix, forming a monolayer of activated platelets that 
can act as a surface for subsequent recruitment of platelets by thrombin, ADP, and 
TxA2. D: During the perpetuation stage, close contact between platelets promote the 
growth and stabilization of the hemostatic plug, in part through contact-dependent 
signaling mechanisms. 
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Initiation begins with the tethering, rolling, and arrest of moving 
platelets on collagen and their subsequent activation to form a platelet 
monolayer. Large VWF multimers are essential to this process, 
particularly under high shear conditions in the arterial circulation, but 
thrombin can also help to initiate platelet activation. Extension refers 
to the recruitment of additional platelets through the local 
accumulation of thrombin, ADP and TxA2. Perpetuation refers to the 
events that stabilize the platelet plug, some of which involves 
molecules on the platelet surface that are capable of generating 
intracellular signals only after platelets have come into sustained 
contact with each other. The net result is the formation of a fibrin-
anchored platelet plug, a structure in which platelet/platelet 
interactions are supported by the binding of fibrinogen and fibrin to the 
integrin αIIbβ3 (also known as glycoprotein [GP] IIb-IIIa) and by VWF 
bound to GP Ib and αIIbβ3 (Fig1.2 ). 
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Figure 1.2 
Anatomy of a platelet plug: an enlarged view of the assembled platelet plug, 
highlighting platelet/platelet interactions mediated by the binding of fibrinogen, fibrin, 
and VWF to activated GP IIb-IIIa (αIIbβ3) and the binding of VWF to GP Ibα. 
 
The contribution of platelets to haemostasis is different in arteries and 
veins. Blood circulates at much higher velocity at the center of a vessel 
compared to near the wall, and this creates are shearing effect 
between adjacent layers of fluid that is greatest at the wall. In the 
venous system, low-flow rates and stasis permit the accumulation of 
activated coagulation factors and the local generation of thrombin, 
with a less prominent contribution from platelets. Venous thrombi 
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contain platelets, but the dominant cellular component consists of 
trapped erythrocytes. In the arterial circulation, higher flow rates limit 
fibrin formation by washing out soluble clotting factors. Platelets, 
which contribute most to thrombosis at higher shear rates, help to 
form a physical barrier against further blood loss and, at the same 
time, provide a surface on which thrombin is generated and fibrin can 
accumulate.  
Shear stress is particularly increased over atherosclerotic lesions 
because significant lumen reduction by obstructive plaques causes a 
local increase in blood flow velocity. Animal studies have shown that 
platelets are not only involved in occlusive thrombus formation leading 
to clinical conditions like myocardial infarction or stroke but may also 
play a prominent role in the promotion of atherosclerotic lesions (63). 
 
1.2. Platelet Function testing 
With platelets being key players in athero-thrombotic events, platelet 
inhibition has been of immense therapeutic interest. The ideal 
antiplatelet drug would be able to overcome the deleterious effects of 
platelets in athero-thrombosis without affecting haemostatic 
functionality. Despite multiple antiplatelet drugs being available for 
therapeutic use, the clinical response to these drugs is variable and 
thus there is a demand for tests to assess platelet function. Platelet 
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function can be assessed in a wide range of clinical scenarios, for e.g. 
in patients with bleeding disorders, in patients with previous thrombo-
embolic events to assess the response to anti-platelet medication, in 
transfusion recipients, in the preoperative setting to assess bleeding 
risk.  Cardiologists, particularly, are interested in the prediction of 
thrombotic events, especially in patients undergoing percutaneous 
coronary intervention and using the most appropriate antiplatelet drug 
to minimize future coronary thrombotic events, such as acute stent 
thrombosis. On the other hand, surgeons are mostly interested in 
knowing about the bleeding tendency, post-operative bleeding risk and 
similar haemostatic issue. Multiple tests are available but identification 
of a single test to answer a question related to platelet function and 
clinical outcome has still not been possible. 
The first stage of assessing platelet function involves measuring the 
full blood count including platelet count and mean platelet volume 
(MPV). If abnormalities are identified in the platelet count, size, or 
distribution, then a blood smear can be examined to confirm these 
findings, and to further assess platelet granule content and 
morphology. This morphological assessment may identify other 
distinguishing features and sometimes is sufficient to make a diagnosis. 
Manual platelet counting still remains the gold standard in assessing 
platelet numbers but requires high levels of technical skill. It is time 
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consuming and most laboratories these days use automated analysers, 
optical counting methods or flow cytometry (64).  This has improved 
their ability to distinguish large platelets from red cells and can 
sometimes provide more accurate counts. 
 
1.2.1 Bleeding Time 
The most simple of the platelet function test is the use of bleeding 
time. The Bleeding Time (BT) was originally described by Duke in 1910 
(65) and further standardized by Ivy et al. in 1941(66). This test can 
be regarded as the oldest test of primary haemostasis investigating 
platelet function. The BT is an in-vivo test in which a small cut is made 
in the forearm of the patient, and the time taken for bleeding to stop is 
measured.  
In the traditional Ivy method, a blood pressure cuff is placed on the 
upper arm and inflated. A stab wound is made on the underside of the 
forearm. The time from the stab wound until all bleeding has stopped 
is measured and is called the bleeding time. Every 30 seconds, filter 
paper or a paper towel is used to draw off the blood. The test is 
finished when bleeding has stopped completely. 
In the Duke method, the wound is made in an ear lobe or a fingertip to 
cause bleeding. In the template technique, a disposable spring loaded 
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device is placed over the area to be stabbed and two incisions are 
made in the forearm using the template as a location guide. 
The BT is subjective and is influenced by patient variables unrelated to 
haemostasis, such as age, gender, haematocrit, vascular pattern, skin 
thickness and skin temperature (67, 68). Although modern BT 
methods show improved standardization and are somewhat sensitive 
to both von Willebrand disease and platelet dysfunction, the BT is now 
rarely used in practice as it is non-specific, has low sensitivity, is 
invasive, and has poor reproducibility due to high rate of inter-
operator variability.  
 
1.2.2 Platelet function analyser (PFA-100) 
The platelet function analyser PFA-100® System (Siemens 
Diagnostics) is a test to determine the thrombosis time automatically 
ex vivo based on the method first described by Kratzer and Born 
(69,70). This test is a microprocessor-controlled instrument (Figure 
1.3) which emulates in vitro the platelet dependent phase of primary 
haemostasis, while delimiting the role of the rheological factors.  
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Figure 1.3: PFA-100 system. (Adapted from the web: 
http://usa.healthcare.siemens.com/hemostasis/systems/pfa-100) 
Basically, the system monitors platelet interaction on collagen-ADP or 
collagen-epinephrine coated membranes. Samples of citrated whole 
blood are drawn under controlled flow conditions (through a capillary 
producing high shear forces: 4,000-5,000/s) through a 150 
micrometre aperture cut within a membrane coated with either 
collagen and epinephrine or collagen and ADP. These agonists induce 
platelet adhesion, activation and aggregation leading to rapid occlusion 
of the aperture and cessation of blood flow termed the closure time. 
Thus, the haemostatic capacity of the platelets in the blood sample is 
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indicated by this closure time. The PFA-100 was designed as a screen 
to detect problems with primary haemostasis and in part to replace the 
bleeding time and in this respect, it is better standardized. It only 
requires small volumes of citrated venous blood [800µL] and so the 
test is useful for investigating platelet function in children. It can be 
used by non-skilled personnel and is both rapid and automated. On the 
other hand, it is dependent on platelet numbers, haematocrit, vWF, 
drugs, food and other acquired platelet disorders (for e.g. uremia, liver 
disease). 
 
The PFA-100 has a high negative predictive value, in other words, if it 
gives a normal result then with some exceptions (e.g. Primary 
Secretion Defects, mild Type 1 VWD) primary haemostasis is intact 
and thus may obviate further screening of platelet function, while if 
the PFA-100 is abnormal then formal platelet aggregation testing will 
be required to establish the underlying cause. Thus at present, its use 
is mainly limited to research studies and clinical trials. 
 
1.2.3 Light transmission aggregometry (LTA)  
The concept of light aggregometry was invented in the 1960’s (70) and 
is widely considered as the gold standard in platelet function testing. 
Despite this, there is still lack of international standardisation of this 
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technique. In this method, platelet aggregation in response to an 
agonist is detected in platelet-rich plasma (PRP) by turbidometry. In 
the Born aggregometer, citrated blood samples are centrifuged to 
prepare platelet rich plasma (PRP) and platelet poor plasma (PPP). To 
prepare PRP, a whole blood tube is centrifuged at 170-200 g for 10 
minutes in a swing-out rotor at room temperature without application 
of the brake. Some laboratories dilute the PRP to a final platelet count 
of 200-300 x 109/l with autologous PPP (71). PRP is stirred in a 
cuvette at 37°C and the cuvette sits between a light source and a 
photocell. The turbidity of the suspension is constantly measured by 
recording transmission of a light beam directed through it, and it is 
recorded as a change in voltage on a chart recorder. When an agonist 
is added the platelets aggregate and absorb less light and so the light 
transmission increases progressively and this is detected by the 
photocell, producing an "aggregation trace" on the recorder 
(Figure1.4). The machine is calibrated for each sample so that the 
platelet suspension to be studied reads 5%-that is, minimum 
transmission-and the corresponding platelet poor plasma reads 95% 
(maximum transmission) (71). 
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Figure 1.4 Legend: Depiction of Born principle of LTA: PRP is stirred in a 
cuvette at 37°C and the cuvette sits between a light source and a photocell. The 
turbidity of the suspension is constantly measured by recording transmission of a 
light beam directed through it, and it is recorded as a change in voltage on a chart 
recorder. When an agonist is added the platelets aggregate and absorb less light and 
so the light transmission increases progressively and this is detected by the photocell, 
producing an "aggregation trace" on the recorder. 
(Adapted from: http://practical-haemostasis.com) 
 
  
The fundamental advantage of LTA is that it measures, albeit in an in 
vitro system, a very important function of platelets: the kinetics of 
their aggregation in a glycoprotein IIb/IIIa dependent manner. 
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There are many variables, which can affect the LTA results, ranging 
from pre-analytical factors (for e.g. drugs, food, temperature, pH etc), 
sample collection and PRP preparation techniques, to the type and 
concentration of agonists used. Commonly used agonists in routine 
practice are ADP, collagen, ristocetin, arachidonic acid, adrenaline, and 
PAR-1-activating peptide (TRAP-6, SFLLRN). The panel of agonists can 
be extended. Other agonists are, for example, gamma thrombin or 
alpha thrombin, TRAP-4 (AYPGKF), thromboxane mimetic U46619 
(stable analogue of the endoperoxide prostaglandin H2) calcium 
ionophore A23187, polymerized immunoglobulins, collagen-related 
peptide (CRP) misfolded proteins like AGE-proteins and oxLDL, alpha 
defensins, proteins from microorganisms like EAP and snake venoms 
like convulxin (72).  
LTA overall is an expensive, time consuming, not readily reproducible 
test, lacking a standard protocol, which makes it unsuitable for 
widespread routine use in clinical practice. 
 
1.2.4 Whole blood aggregometry 
To overcome the technical and physiological issues associated with 
traditional aggregometry the impedance aggregometer was invented in 
1980’s (73) In this technique whole blood is stirred at 37°C and 
aggregation is detected by the accretion of platelets to the surface of 
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two fine, precious metal, wire electrodes, The impedance technique 
measures the progressive increase of electrical impedance between 
two electrodes as platelets adhere and aggregate to these electrodes 
in stirred whole blood. Some of the technical problems of whole blood 
impedance aggregation have been overcome by the development of 
disposable electrodes, standardised reagents and the availability of a 5 
channel multiple electrode platelet aggregometer (Dynabyte, Munich, 
Germany) (74) 
There is still lack of comparative data between whole blood and 
traditional aggregometry and thus its use is limited in practice. It also 
requires specialist skills, equipment and is a lab based test. 
Currently, there are several commercially available instruments for 
measuring platelet aggregation based on the principles of light 
transmittance, impedance, luminescence and some in combination.  
 
1.2.5 Flow cytometry 
A flow cytometer operates as a cell counter, that uses argon ion laser 
as an excitation light source to additional detectors for fluorescence 
signal measurement. This allows gathering information on the size and 
internal complexity (forward scatter and side scatter, respectively) as 
well as markers, identified by staining with fluorescent probes. Before 
analysis, platelets are labelled with a fluorescently conjugated 
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monoclonal antibody. The cell suspension then passes through the flow 
chamber, through a focused laser beam that activates the fluorophore. 
The emitted fluorescence and scattered light characteristics can then 
be used to identify the cells of interest. 
 
Flow cytometry can be used to yield definitive information regarding 
the phenotypic status of platelets. It allows the analysis of individual 
platelet functional capability and quantitative assessment of the 
physical and antigenic properties of platelets e.g. the expression of 
surface receptors, components of granules, bound ligands, and 
interaction of platelets with other platelets, neutrophils and monocytes 
thereby facilitating the diagnosis of inherited or acquired platelet 
disorders (e.g., Bernard-Soulier syndrome, Glanzmann thrombasthenia, 
storage pool disease), the pathological activation of platelets (e.g., in 
the setting of acute coronary syndromes, cerebrovascular ischemia, 
peripheral vascular disease, cardiopulmonary bypass), and changes in 
the ability of platelets to activate via specific stimuli (e.g., efficacy of 
antiplatelet therapies) (75).  
 
Flow cytometry allows identification of platelet function defects even in 
patients with very low platelet count and therefore is the methodology 
of choice to determine whether a thrombopenic patient has in addition 
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a thrombocytopenia. It remains an expensive and technically 
demanding method and requires careful sample preparation. (76) 
 
Measuring the phosphorylation state of vasodilator stimulated 
phosphoprotein (VASP) using flow cytometry is a completely P2Y12-
receptor specific method for the evaluation of ADP-receptor inhibition. 
VASP is a second messenger in the signalling pathway of the P2Y12 
receptor that is regulated by protein kinases and phosphatases 
according to the activity of the receptor. 
 
Inactive/resting platelets possess high cAMP levels that induce 
phosphorylation of VASP by cAMP-dependent protein kinases (VASP-P: 
resting state). In case of P2Y12-receptor stimulation, the activity of 
the adenylate-cyclase enzyme decreases leading to dephosphorylation 
of VASP (VASP: active state). Therefore, the ratio of dephosphorylated 
and phosphorylated VASP is a selective measure of P2Y12-inhibition 
unaffected by use of glycoprotein IIb/IIIa inhibitors. 
 
1.2.6 Platelet nucleotide assays  
Platelets have two separate nucleotide pools within them. Sixty 
percent is stored within the dense granules and is not metabolically 
active and the remaining 40% constitutes the metabolic pool and 
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provides the platelet with energy for various activities. The ratio of 
ATP: ADP is therefore of fundamental importance as there are 
pronounced differences between the relative concentrations in the two 
pools. Any storage defects are associated with a decrease in the 
amount of stored and released ADP with an increased ratio of ATP: 
ADP. Thus the measurement of total or released nucleotides along with 
aggregometry provides additional information of platelet disorders 
regarding any storage pool disorders or degranulation defects. 
The simplest assay of released platelet nucleotides can be performed 
in real time with a Lumi-Aggregometer (77). This is a modification of 
light transmission aggregometry, which measures ATP release from 
the dense granules. It is based on quantitative bioluminescent 
determination of ATP in which the ATP reacts with luciferin and 
luciferase [firefly extracts] resulting in light emission.  Light is emitted 
when oxidation of adenyl-luciferin occurs. 
For measurement of aggregation, the lumi-aggregometer uses an LED 
which emits light in the infrared range and changes in the transmission 
of light are detected by a phototransistor. For the measurement of 
luminescence resulting from ATP secretion, it uses a photomultiplier 
tube located at right angles to the light path of the LED.  
Dense granules are normally easily visible on electron microscopy and 
thus can be directly measured. It is possible to measure the uptake 
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and release of radiolabelled serotonin into and from the platelets with 
standardised assays as serotonin is actively taken up and stored within 
the platelet dense granules. Flow cytometry can also be used to 
measure the mepacrine uptake and release from dense granules.  
(78). 
 
1.2.7 VerifyNow 
VerifyNow Rapid Platelet Function Analyser (Accumetrics, San Diego, 
CA) is a point of care instrument (Figure 1.5). This assay is based on 
light aggregometry. The principle of this assay is that fibrinogen-
coated polystyrene micro-particles will agglutinate in whole blood in 
direct proportion to the degree of platelet activation and subsequently 
activated glycoprotein (GP) IIb/IIIa receptors (79). 
The tube containing the whole blood sample is inserted into a 
disposable plastic cartridge containing a lyophilized preparation of 
human fibrinogen-coated beads, a platelet-activating agent, buffer and 
preservative. The whole blood is first heated to 37ºC before being 
automatically drawn into a sample channel containing the platelet 
agonist and fibrinogen-coated beads and is then mixed by the 
movement of a microprocessor-driven steel ball. The light absorbance 
of the sample is measured 16 times per second by an automated 
detector. As the platelets interact with the fibrinogen-coated beads, 
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resulting in agglutination, there is a progressive increase in light 
transmission. A patient’s blood sample that exhibits inhibited platelet 
function produces low light transmittance; whereas a sample with 
normal platelet function produces high light transmittance. The rate of 
agglutination is quantified as the slope of the change of absorbance 
over a fixed time interval and measured in millivolts per 10 s. The 
device then automatically displays this result in agonist-specific units. 
This system measures the rate of platelet response but not the extent 
of aggregation response; thus, data obtained from this system are 
more similar to slope determinations in classic LTA (80). 
 
 
Figure 1.5: VerifyNow Instrument (Accumetrics, San Diego, CA) 
{Adapted from:  http://www.accumetrics.com/) 
Three types of cartridges are available for use with VerifyNow: one for 
measuring the effects of aspirin, another for P2Y12 inhibitors and a 
third for GP IIb/IIIa inhibitors. 
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So far, clinically, there has been poor correlation between the results 
of LTA and VerifyNow in assessing antiplatelet drug response (81). 
 
1.2.8 Viscoelastic point-of-care haemostatic assays (VHA) 
The VHA gives a graphic presentation of clot formation and subsequent 
lysis. Thrombelastography (TEG) (figure 1.6) was first described in 
1948 by H. Hartert (82) as a method to assess the viscoelastic 
properties of coagulation in whole blood under low shear conditions. 
Rotation Thromboelastometry (ROTEM®) is another technique 
(Figure1.7). These measure the physical properties of a forming clot 
by the use of an oscillating cup. Whole blood is incubated at 37°C in a 
heated cup. Within the cup is suspended a pin connected to a 
mechanical–electrical transducer that monitors the motion of the pin 
(a torsion wire in TEG and an optical detector in ROTEM). The cup and 
pin are oscillated relative to each other through an angle. The 
movement is initiated from either the cup (TEG) or the pin (ROTEM). 
As fibrin forms between the cup and pin, the transmitted rotation from 
the cup to pin (TEG) or the impedance of the rotation of the pin 
(ROTEM) are detected at the pin and a trace generated. The trace is 
divided into parts that each reflects different stages of the haemostatic 
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process (clotting time, kinetics, strength and lysis, with slightly 
different nomenclature for TEG and ROTEM) (83). 
 
Figure 1.6: TEG® 5000 Thrombelastograph® Hemostasis Analyzer System. 
(Adapted from: http://www.haemonetics.com/Products/Devices/surgical) 
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Figure 1.7 ROTEM Instrument. 
 (Adapted from: https://www.rotem-usa.com/products) 
 
Maximal haemostatic activity is measured by a kaolin-activated whole-
blood sample treated with citrate. Heparin is used as an anticoagulant 
to eliminate thrombin activity in the sample. Reptilase and factor XIIIa 
(activator F) are used to generate a cross-linked fibrin clot to isolate 
the fibrin contribution to clot strength. The contribution of the ADP or 
TxA2 receptors to the clot formation is provided by the addition of ADP 
or AA. The effect of aspirin or thienopyridine therapy also can be 
estimated by comparing the unmodified TEG curve (i.e., kaolin-
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activated whole-blood sample) with the AA or ADP-stimulated TEG 
curve (84).  
 
1.2.9 Platelet works 
It is also possible to monitor platelet aggregometry in whole blood by 
a simple platelet counting technique. The Plateletworks (Plateletworks 
aggregation kits and Ichor full blood counter, Helena Laboratories, 
Beaumont, TX) methodology involves using a cell counter to measure 
total platelet count in a whole blood sample and then to repeat the 
platelet count on a second sample that has been exposed to a known 
platelet agonist. After this the platelets aggregate and the platelet 
count decrease compared to the first sample. Aggregated or 
agglutinated platelets will not be counted as platelets in the second 
sample (85). 
The difference in platelet counts between the two samples provides a 
measure of aggregation, whereas the ratio of the two counts provides 
a measure of percentage inhibition. 
 
1.2.10 Global Thrombosis Test 
The Global Thrombosis Test (GTT, Montrose diagnostics, UK. Figure 
1.8) is the first clinically available, comprehensive, point-of care test to 
simultaneously measure thrombotic occlusion time (OT), coagulation, 
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and spontaneous endogenous thrombolytic activity. The apparatus is 
pre-warmed to 37 degrees before use for testing. In this test the 
platelets are activated by high shear stress, without any other 
agonists. The collected blood is passed through a specially designed 
plastic conical tube containing narrow gaps (created by the gaps 
between the inside of the tube and two ceramic ball bearings inside). 
As blood passes through these narrow gaps, platelets are exposed to 
high stress conditions, similar those shear stresses that exist in a 
stenosed coronary artery. This causes platelets to be activated. The 
flow of the blood is monitored downstream with a light source and 
used to measure the arrest of flow suggesting total occlusion of the 
lumen and the time to restart flow due to spontaneous thrombolysis of 
the platelet plug (86). This test uses native, non-anti-coagulated whole 
blood and thus overcomes the shortcomings of many other tests. 
Although the initial activating stimulus is high shear stress, in the 
development of occlusive thrombi all physiologically-important platelet 
agonists (TXA2, ADP, thrombin) are closely involved. GTT only requires 
One 4.0 ml blood sample can be done by bed side. There is no 
calibration or internal standard required. 
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Figure 1.8: GTT instrument and tube.  
(Adapted from http://www.nutr.kobegakuin.ac.jp/~seiri/english/images/GTT) 
 
1.3. Limitations of platelet function tests 
 
Despite the availability of a multitude of tests, there has been no 
single test that can adequately address all the issues with respect to 
platelet related disorders. Although, light transmission platelet 
aggregometry is regarded as the gold standard of platelet function 
test, it is relatively non-physiological because separated platelets are 
usually stirred under low shear conditions during the test and only 
form aggregates after the addition of agonists, conditions that do not 
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accurately mimic platelet adhesion, activation and aggregation upon 
endothelial injury. Conditions which impair light transmittance, for e.g. 
lipaemia and haemolysis will significantly affect LTA results. 
Conventional LTA using a full panel of agonists requires both high 
blood volumes and expertise to carry out and interpret results and 
thus makes it an impractical test for routine clinical use 24 hours a 
day, 7 days a week.  
Furthermore, currently, all platelet function tests are performed on 
citrated PRP or whole blood. Citrate anticoagulation interferes with 
ionised calcium. The presence of calcium is essential for platelet 
aggregation and release of dense granular nucleotides and in a citrated 
sample all extracellular calcium gets bound with ethylenediamine-
tetraacetic acid, thus irreversibly hampering platelet aggregation (87). 
Plasma Ca2+ is not constant, but varies with haematocrit between 
individuals, with exercise, and in various disease states such as 
hypertension, asthma, and diabetes. Despite the use of a fixed 
citrate:blood ratio, therefore, the actual Ca2+ concentration in citrated 
blood will vary considerably. Citrate reduces the plasma Ca2+ 
concentration from 0.94–1.33 mM to 40–50 μM. Platelet aggregation is 
optimum at levels of 100 μM Ca2+, and at levels below 10 μM, platelet 
aggregation does not occur. Accordingly, a slight alteration in the 
circulating plasma Ca2+ level will manifest in markedly enhanced or 
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reduced agonist-induced platelet aggregation and response to 
antiplatelet agents in blood. In citrated blood, thrombin is not 
generated, and Ca2+ levels are significantly reduced to 40–50 μM 
(below the threshold level of 250 μM required to generate thrombin), 
resulting in suboptimum platelet aggregation (88) 
The citrated sample is tested between 30 min and 4hour of collection 
assuming constant platelet behaviour but the responsiveness of 
platelets to aggregating stimuli changes with time (88). If the platelet 
function test is performed within minutes of blood draw, aggregation in 
response to almost all stimuli is minimal. Maximum aggregation is 
demonstrated only about 1 hour after collection of blood. The time 
taken for platelets to become responsive can be reduced by increasing 
the concentration of some agonists but this may require large 
concentrations of the agonists due to inter-individual variations and 
reduce the sensitivity of the test. This makes it impossible to 
determine the optimal storage time of the sample (88). Other factors 
like the procedure of collection of blood and agonists used may also 
interfere in the accurate assessment of platelet aggregation. Most of 
the platelet function tests described above are single agonist specific, 
in other words, they only measure response of platelets to one 
particular agonist for e.g. ADP, epinephrine, arachidonic acid or 
collagen. The effect of shear stress is not measured in these tests. 
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Also, overall thrombolytic status is difficult to measure using these 
platelet function tests as most of these tests do not measure the 
response to all fibrinolytic markers. Thus none of the test provides an 
assessment of global thrombotic status of an individual patient. 
GTT has an advantage as it is performed on native blood within 15 
seconds after collection; involves shear stress, and is able to assess 
the effect of thrombin on thrombosis. It also assesses endogenous 
thrombolytic activity and hence seems to be a more physiological test 
than any other tests available currently albeit with limited clinical data. 
 
1.4 Correlation of PFT with clinical outcome 
Clinical correlation between measured platelet function and 
cardiovascular outcome has been poor despite use of different tests 
(89). 
Recently, in a multi-centre randomised French study, 2440 patients 
with stable angina or non-ST-elevation acute coronary syndrome 
undergoing PCI were randomised to either conventional antiplatelet 
strategy or to a monitoring-guided strategy for drug-eluting stent 
implantation with drug adjustment in patients with poor antiplatelet 
response. For patients in the monitoring group, the VerifyNow P2Y12 
and aspirin point-of-care assays were used in the catheterization 
laboratory before stent implantation and in the outpatient clinic 2 to 4 
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weeks later.  The primary end point was the composite of death, 
myocardial infarction, stent thrombosis, stroke, or urgent 
revascularization 1 year after stent implantation. In the monitoring 
group, high platelet reactivity in patients taking clopidogrel (34.5% of 
patients) or aspirin (7.6%) led to the administration of an additional 
bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein 
IIb/IIIa inhibitors during the procedure. The primary end point 
occurred in 34.6% of the patients in the monitoring group, as 
compared with 31.1% of those in the conventional-treatment group 
(hazard ratio (HR), 1.13; 95% confidence interval [CI], 0.98 to 1.29; 
P=0.10). Interestingly, the main secondary end point, stent 
thrombosis or any urgent revascularization, occurred in 4.9% of the 
patients in the monitoring group and 4.6% of those in the 
conventional-treatment group (HR 1.06;95%CI, 0.74 to 1.52; p=0.77). 
The rate of major bleeding events did not differ significantly between 
groups. Thus the authors concluded that there were no significant 
improvements in clinical outcomes with platelet-function monitoring 
and treatment adjustment for coronary stenting, as compared with 
standard antiplatelet therapy without monitoring (90). 
Updated American and European practice guidelines have issued a 
Class IIb recommendation for platelet function testing to facilitate the 
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choice of antiplatelet agent in selected high-risk patients treated with 
PCI, although routine testing is not recommended (Class III) (91). 
 
The strategy of monitoring platelet function to yield better ischemic 
and safety outcomes might be still limited by at least one factor: what 
is the optimal platelet function test? Thus, the quest for an ideal 
platelet function test, which will not only provide quantitative data 
regarding platelet functionality but will also reflect on clinical outcomes 
and aid decision making in individual patients is still on going. 
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Chapter 2: 
Hypothesis and 
Aims 
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2.1 Hypothesis: 
Chronic renal failure patients despite being on RRT (dialysis or having 
undergone a renal transplant) remain at increased risk of acute 
thrombotic events. The reason for this is unclear, but may be related 
to either increased platelet reactivity (tendency to activate and 
aggregate), impaired endogenous thrombolytic activity or both. For 
the purpose of this study, we hypothesised that there are differences 
in either the aggregatibility of the platelets or the tendency of 
spontaneous thrombolysis of a formed platelet rich thrombus in ESRD 
patients, which may account for their increased thrombotic events, 
over and above traditional risk factors.   
 
2.2 Aims: 
The aims of this project were as follows: 
1) To characterize thrombotic status, using the Global Thrombosis Test 
(Montrose diagnostics, London, U.K) in ESRD patients  
2) To compare the thrombotic status of the ESRD patients with that of 
normal healthy volunteers and patients with known coronary artery 
disease but no renal disease. 
3) To investigate whether a platelet function test of overall thrombotic 
status could identify those patients who despite RRT, remain pro-
thrombotic and/or have impaired endogenous thrombolysis.  
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4) To observe whether any variation of platelet reactivity in renal 
disease patients is related to an increase in acute thrombotic events.  
5) To identify whether there are any variations in platelet function 
within patients on different modes of RRT (HD vs. peritoneal dialysis 
(PD) vs. renal transplant recipients) 
6) To identify whether certain clinical subgroups are more likely to be 
prone to acute thrombotic events (for e.g. women, Asians, diabetics).  
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Chapter 3: 
Methods 
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3.1 Study population 
The main study group was of the patients with ESRD undergoing HD 
for at least 3 months under supervision of the East and North 
Hertfordshire NHS Trust renal department. These patients were 
receiving treatment by regular HD at the Lister Hospital, Stevenage, or 
its satellite units at St Albans City Hospital, St. Albans, and Luton and 
Dunstable Hospital, Luton. Further subgroups included patients with 
renal transplant under the care of Lister Hospital and patients on PD 
supervised by the Lister Hospital. The subgroups will be discussed later 
in separate chapters. 
 
3.2 Inclusion criteria:  
All patients aged 18-90 years and who met the criteria for ESRD on 
RRT as described above, who were able to consent and did not have 
any exclusion criteria as described below were approached for 
participation in the study. 
 
3.3 Exclusion Criteria:  
The following exclusion criteria were applied to this study: 
• Inability to consent 
• Current participation in another interventional study 
• >90 years and <18 years 
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• ST-segment elevation myocardial infarction within 2 weeks 
• Cardiogenic shock 
• Inter-current illness, such as pneumonia, sepsis, ACS or heart 
failure in last 3 months  
• Malignancy (active) 
• Bleeding diathesis 
• When complete follow up over 1 year period was unlikely (e.g 
patients planned for live-donor transplant or planned to move out of 
the area. 
• Other disease (non –cardiac conditions) shortening life-expectancy 
to less than 12 months 
• Blood dyscrasia (platelets <70, Hb <8g/dl, INR>1.4, APTT>x2 ULN, 
leukocyte count <3.5x 109/l, neutrophils count <1 x 109/l) 
• Warfarin or other anticoagulant treatment 
• Thrombolysis or glycoprotein IIb/IIIa inhibitor prior to sampling 
(within last 7 days). 
 
3.4 Funding and Ethics: 
The funding for the project was provided by the cardiovascular 
research department of the East and North Hertfordshire NHS Trust. 
The study protocol was then submitted to the local ethics committee 
(Essex and Hertfordshire research network). The ethics committee 
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approved the study protocol and documents after an application form 
submission process followed by an interview of the researchers by a 
specialist panel. The letter of approval is available to view in the 
appendix section. 
The protocol was approved by the research and development 
department of the trust after an application and review process. 
 
3.5. Patient selection and consenting  
3.5.1 Haemodialysis patients  
A list of all the patients undergoing HD was obtained on weekly basis 
from the schedule available in each individual unit and patient notes 
were reviewed to screen eligible patients. 
The patients were approached by me during their attendance to 
discuss the study on a face-to face basis individually. Explanation was 
provided that this is purely a research study and will not affect their 
clinical outcome or management in any way. All patients approached 
were informed that participation is entirely voluntary and would not 
benefit them directly and that they would be free to withdraw from the 
study at any time and it would not impact on their current or future 
clinical care. They were also made aware of the follow up procedure 
and need for repeat contact as part of the study. A patient information 
sheet (appendix), which was approved by the local ethics committee, 
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was provided to each patient on individual basis and at least 48 hours 
were given before re-approaching patients regarding their decision 
about participation. If the patients decided to participate in the study 
then a full informed, written consent was obtained in all cases. A 
consent form which was approved by the local ethics committee was 
used (appendix). 
 
3.5.2 Peritoneal dialysis and Renal transplant recipients  
Patients on PD under supervision of the Lister hospital and all renal 
transplant recipients were approached for participation in the study on 
the day of their out-patient appointment at the Lister hospital. They 
were provided information in same manner as described above for the 
HD patients. They were re-approached for consent and sampling only 
on the day of their next clinic appointment. 
 
3.6 Sample collection 
Most patients in all the units have a fixed time table which is 
generated beforehand and they attend the dialysis units at a pre-fixed 
times and days of the week with flexible arrangements in place, by all 
the units, to accommodate any patient requests for time or day 
alteration due to personal or clinical reasons.  As all the patients were 
approached to discuss the study and provided with leaflets beforehand, 
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the consent for participation was obtained in advance to the sampling 
date. The sampling time and date was then agreed with the patient 
according to their time slot for dialysis. In all units there were four 
slots available to patients – early morning (commencing at 07:00 
a.m.), mid-day (12:00 p.m.), early (15:00 p.m.) and late evening 
(18:30 p.m.). 
I use to arrive at the renal unit approximately 30 minutes before the 
scheduled patient dialysis time to get the GTT machine ready (pre-
heat according to the GTT protocol as discussed in chapter 1 section 
2.7.4) and also to set up the machine and identify a suitable place to 
sample the patient without causing interference with their own or any 
other patient’s treatment attending the dialysis unit at the time. The 
majority of time, the machine was placed at the bedside of the patient 
but if this was not possible (usually when two patients’ beds were very 
close making it difficult to move freely or if an electric plug was not 
available near the bed for the GTT machine) then an appropriate area 
within the dialysis unit was used to place the machine and patient 
sample was obtained there. This usually was the area where patients 
are weighed prior to the start of HD on the day. Depending upon the 
number of GTT machines being available on the day of the sampling, 
either 2 or 4 patients were sampled just before any one dialysis time 
slot. As each machine has four ports, it was only possible to sample 2 
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patients using one machine in order to have two samples from each 
patient (one as a control sample to avoid any spurious results and 
minimise operator related errors). As the GTT sampling process is very 
operator dependant, it was a learning curve for me in the first few 
patients and I used up-to four samples in the initial 20 patients to 
minimise any error and develop a consistent technique although only 
valid readings were used from these patients and the non-valid 
readings discarded and not used in subsequent analysis. 
Whole blood was used as part of the protocol to assess the global 
thrombotic status in the study population using GTT. Nine mL venous 
blood was obtained from a peripheral (non-fistula) vein from each 
patient and tested immediately after withdrawal. In all the patients the 
samples were collected by applying the tourniquet for very short 
duration and not very tight to avoid any spurious results caused by 
venous stasis. In HD patients, blood was obtained immediately prior to 
dialysis, before the routine low-molecular weight heparin was 
administered according to local protocol. Low-molecular weight heparin 
is used in the renal unit at the East and North Herts NHS Trust, as a 
single intravenous bolus immediately pre-dialysis. This allowed 
between forty eight to seventy two hours duration between low 
molecular weight heparin administration and GTT sample collection. 
The timing of the sample collection was according to the individual 
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patient’s dialysis schedule start time and to standardise sample 
collection approximately 48 -72 hours post dialysis in all patients. This 
meant although all the patients on HD were sampled approximately 
after a similar gap post the previous dialysis session but sample 
collection was at different hours of the day according to individual 
dialysis time schedule. 
Blood was taken using an 18-gauge butterfly cannula using a three -
syringe technique. Three 5 ml syringes were used for blood collection. 
The first 3ml was either used as a control sample or discarded if there 
was any suspicion of haemolysis or air bubble in the butterfly cannula 
during venepuncture, the next 3-5 mL was used for routine tests 
(blood count, biochemistry, bicarbonate, and bone-profile) and the 
next 3 mL for global thrombotic status assessment. Where the 
quantity of blood obtained was not sufficient the procedure was 
abandoned and patient were re-sampled on a different day, if they 
agreed to it. Where the patients had had some routine tests within  
the last 1 week of sampling then the tests were not repeated and the 
available results were used. Blood was aspirated into a standard 
polypropylene syringe, which was directly and immediately inserted 
into the fitting in the GTT instrument (within 15 s of withdrawal). To 
avoid any sampling delay and to minimise any sample transit time the 
GTT instrument was positioned next to the patient’s bed where 
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possible or in very close proximity. As the GTT instrument can test 
more than 1 patient sample simultaneously, the machine was placed in 
between the patient bays to minimise transit time. When this was not 
possible or the patients were ambulant, then the test was conducted in 
a dedicated room within the dialysis unit before the patients were put 
on dialysis, and the patient brought to that room for blood taking.  The 
syringes were pre-labelled to avoid mixing up of samples. 
Coefficient of variation was assessed by testing 10 healthy volunteers 
twice, at 48 hours interval and also by testing 10 HD patients twice at 
48 hours interval. The coefficient of variation for OT was 8 % in 
normal volunteers and 6 % in HD patients.  
To assess the effect of antiplatelet therapy on thrombotic status of 
normal healthy volunteers a small subgroup (20 healthy volunteers) 
was tested with GTT pre and post antiplatelet drugs. Volunteers were 
tested for GTT and then given a 300mg dose of aspirin and then GTT 
repeated few hours later. This same group, after a month of washout 
phase, was assessed again before and 12 hour after a 300mg loading 
dose of clopidogrel. This was done taking into account the half-lives of 
Aspirin and clopidogrel. Half-life of Aspirin varies according to the dose 
and at lower dose it is short, approximately 2 hours, but at higher 
doses it varies between 15- 30 hours. Clopidogrel has a half-life of 
about 6 hours.  
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3.7 Assessment of thrombotic and thrombolytic status 
3.7.1 Global thrombosis test 
Thrombotic status and endogenous thrombolytic activity were 
assessed using the GTT (Montrose Diagnostics Ltd, UK). This is a novel, 
point-of-care assay that employs non-anticoagulated blood. The GTT 
instrument is portable and easy to carry around (Figure 3.1). It is 
powered using an AC adaptor which can be plugged in any standard 
UK electrical socket. 
 
Figure 3.1: GTT instrument. 
The instrument has 4 channels to take up to four test tubes and thus 
four patient samples simultaneously. Once the machine is plugged into 
the electric mains it starts warming up and the LED indicator lights 
starts flashing. After the instrument is warmed up to 37 degrees 
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centigrade the LED indicator lights go off and the display panel shows 
“GTT ready” message. Any of the four channels can be used for 
sample analysis by choosing the channel number from the key pad on 
the instrument under the display screen. Once the sample is inserted 
in to the test tube inside a channel, the start button can be pressed on 
the key pad and the LED indicator light turns green. The LED indicator 
light of the channel in use remains green during sample analysis and 
turns amber once occlusion time reading is available (described below) 
and finally red once analysis is complete. 
 
The instrument measures the time taken to create shear-induced 
thrombi under pathophysiological conditions (discussed previously in 
chapter 1) and in the second phase of the test, measures the time to 
achieve spontaneous lysis of thrombi created during the first phase. 
The principle of the GTT described below and is shown in Figures 3.2 
and 3.3.  
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FIGURE 3.2: Mechanism of GTT 
 (Adapted from www.globalthrombosis.com) 
Blood is introduced into a plastic tube in which two metal balls are 
situated in the conical part of the tube. The blood flows through this 
conical tube, which has got an outer cylindrical glass test tube for 
collection of downstream flow. There are four narrow gaps between 
the inner plastic surface and the balls (Figure 3.2). When blood flows 
through these gaps adjacent to the upper ball, the resulting high initial 
shear stress (180 dynes/cm2) causes activation of platelets. In the 
space between the balls, due to the turbulent flow and low shear, the 
activated platelets aggregate. Thrombin is generated, which 
accelerates the formation of these aggregates and stabilizes them 
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through fibrin. When these stable thrombi reach the gaps around the 
lower ball, they gradually occlude these gaps, reducing the flow rate 
and finally arresting flow. The instrument measures the time (d) 
between consecutive blood drops. At the start of the test, flow is rapid 
and hence (d) is small. Subsequently, the flow rate decreases and 
hence (d) increases. When, the actual d ≥15 sec, the time (first 
reading marked T1 on the instrument display panel) is displayed 
as Occlusion Time (OT sec). Subsequently the flow completely ceases. 
There is also a preset “thrombus stabilization time” following OT (200 
sec), during which the sensors are inactive. This time is to allow 
stabilization of the formed thrombi, lasting occlusion and ignores small 
re-bleeds. Eventually, due to endogenous thrombolysis, flow is 
(partially) restored as indicated by detection of the first blood drop 
after OT (marked T2 on the instrument display panel). Lysis Time (LT 
sec) is calculated automatically by the instrument using the formula, 
LT= T2 – (T1+200). 
The restart of blood flow following occlusion is due to spontaneous 
thrombolysis (lysis time, LT; seconds). If lysis does not occur until 
6000 s following OT (LT cut-off time), ‘no lysis’ is recorded. 
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Figure 3.3: Principle of GTT (Explanation in text) 
(Adapted from www.globalthrombosis.com) 
The GTT assesses thrombus formation under pathophysiological 
conditions, since (i) whole blood is used which is non-anticoagulated, 
with physiological calcium-ion concentration, (ii) similar to pathological 
conditions, platelet-rich thrombus formation is initiated by high shear 
forces, with release of soluble agonists (TXA2, ADP, thrombin) playing 
only a secondary role, and (iii) thrombin generation from shear-
activated platelets (procoagulant activity of platelets) plays a major 
role in the formation and stabilization of thrombi (92). As soluble 
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agonists are involved in the process of thrombus generation there is 
no need for several tests with different platelet agonists.  
 
There was a small sub-study conducted prior to starting recruitment 
for the main study population (HD patients). This study which is 
discussed in detail in Chapter Five assessed consecutive GTT results 
from 2 locations in 20 patients. In each patient there were two 
samples obtained, one from a peripheral vein and the second from the 
fistula site at the time of HD. Both samples were used to assess 
thrombotic status by using GTT machine as described previously. The 
comparison showed variation in the OT and LT results obtained from 
the two sites and thus to maintain uniformity and prevent any error it 
was decided to use the peripheral venous sample to obtain GTT results 
for the planned main study (HD) population.   
 
3.8 Data collection and follow-up 
3.8.1 Data Collection 
Baseline demographics, including dialysis vintage, were collected from 
the central electronic data base of all the RRT patients under the renal 
unit of the E&N Hertfordshire Trust. I received training in the use and 
interrogation of the database by the dedicated staff responsible for the 
running and maintenance of the software. The urea kinetic adequacy 
  
[ S u m e e t  S h a r m a ]  
 
Page 89 
parameters relating to the previous month’s routine testing were also 
collected. Past medical history and any relevant clinical information 
were also identified from the data base or previous clinic letters.  
 
This included the aetiology of renal disease where available, all past 
and present medical conditions, full drug history and history about 
previous and current renal replacement modality. The study patients 
were given a unique study reference number and all the data was kept 
anonymous to prevent exposure of any personal and demographic 
details. All further analysis and data interpretation was done using the 
patient’s study number and no patient-identifiable information was 
used. All the data was collected on a pre-designed data collection form, 
which had been approved by the ethics committee (appendix). 
 
Post collection, data was transferred onto Microsoft Excel software for 
keeping record and also for analysis purposes. All paper data was 
anonymised and the original data collection forms are all kept locked 
in the cardiology research office at the Queen Elizabeth 2 Hospital, 
Welwyn Garden City. The patient consent forms are also kept in a 
similar fashion in a dedicated folder in the cardiology research office. 
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A letter was sent to the general practitioner of the participating 
patients after prior approval from the patients. This letter format was 
also approved by the local ethics committee. This is available in the 
appendix section. 
 
3.8.2 Follow-up 
Follow-up was performed at 30 days and then at 3-monthly intervals 
for up-to a year in all patients. Some patients were followed up even 
after 1 year depending on time of recruitment into the study and 
patient willingness. The data beyond 1 year was not used in analysis 
as it was only available in small proportion of patients. Where possible 
the follow-up was done in the dialysis unit by a face to face interview 
with the participating patients. The proforma used is available in the 
appendix section.  Where it was not possible to visit the patient during 
dialysis session, then a telephone contact was made with prior 
permission from the patients, which was obtained at the time of 
consenting. 
 
3.9 Study endpoints 
The primary endpoint of the study was the occurrence of major 
adverse cardiovascular events (MACCE) defined as the composite of 
cardiovascular death, non-fatal myocardial infarction (MI), or 
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cerebrovascular event. The secondary endpoint was the occurrence of 
peripheral vascular thrombosis including acute ischaemic limb and 
arterio-venous (AV) fistula thrombosis.  
 
3.9.1 Cardiovascular events 
New cardiovascular events were diagnosed in the presence of following 
two clinical events: 
(I) Cardiovascular death, defined as death from MI based on the 
Universal Definition of Myocardial Infarction (93) This has been defined 
as sudden, unexpected cardiac death, involving cardiac arrest, often 
with symptoms suggestive of myocardial ischaemia, and accompanied 
by presumably new ST elevation, or new left bundle branch block, 
and/or evidence of fresh thrombus by coronary angiography and/or at 
autopsy, but death occurring before blood samples could be obtained, 
or at a time before the appearance of cardiac biomarkers in the blood), 
significant arrhythmia, or refractory congestive heart failure, or death 
attributed to cardiovascular cause at post-mortem; confirmed from 
death certificates as well as medical records and observers’ accounts; 
sudden death was included as a cardiovascular event. 
 (II) Non-fatal MI, defined according to the Universal Definition of 
Myocardial Infarction as a rise and/ or fall of cardiac troponin with at 
least one value above the 99th percentile of the upper reference limit 
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together with evidence of myocardial ischemia with at least one of the 
following: symptoms of ischemia; ECG changes indicative of new 
ischemia (new ST-T changes or new left bundle branch block); 
development of pathological Q waves in the ECG; or imaging evidence 
of new loss of viable myocardium or new regional wall motion 
abnormality. 
 
3.9.2 Cerebrovascular events 
New-onset cerebrovascular event was suspected with recent onset of 
neurological symptoms or signs, e.g. aphasia, focal deficits, or 
unilateral paresis, thought to be vascular in origin and confirmed by 
computerized tomography (CT) or MRI brain. This included events with 
and without spontaneous clinical resolution, and thus included both 
stroke and transient ischaemic events. 
 
3.9.3 Cause of death 
Deaths were classified based on data obtained from post-mortem, 
from hospital medical records, or from the general practitioner, 
regarding the patient’s last illness, according to WHO criteria based on 
ICD 10 (2010). 
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3.9.4 Secondary Endpoints 
Peripheral thrombotic events were defined as occurrence of acute 
ischaemic limb(s) or AV fistula thrombosis on clinical examination and 
confirmed by contrast angiography and/or duplex ultrasound. 
AV fistula thrombosis was included since this bears many similarities to 
arterial thrombosis. It occurs in the presence of arterial blood, under 
systolic pressure and pulsatile flow. In 80% of cases, it is associated 
with a significant stenosis, at or close to the AV anastomosis, 
predominantly due to intimal hyperplasia and associated with 
inflammation (94, 95). Abnormal haemodynamic shear stress is the 
most important upstream factor responsible for AV fistula failure. High 
shear rates upstream of a stenosed AV fistula predispose to platelet 
thrombus formation (rather than erythrocyte- and fibrin-rich thrombi 
formed in low shear, venous settings) and this is supported by 
histological findings. 
 
3.10 Study end point data collection.  
Once a clinical event was identified in a participating patient, further 
details were sought to confirm achievement of study end point. This 
was done where possible without checking the results of the GTT test 
in the patient to minimise any bias. 
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Clinical event was confirmed by details of individual event obtained 
from the medical records and analysis of laboratory results. If the 
clinical event was cardiovascular the information was also confirmed 
from any cardiological intervention or investigation records. In 
cerebrovascular events the results of any form of brain imaging or 
specialist neurological input were sought to confirm an event. In rare 
cases of events happening out of the catchment area of the East and 
North Hertfordshire NHS Trust, the details were obtained from 
patient’s GP, discharge summaries from other hospital and relevant 
documents (imaging or cardiac catheterisation reports) were obtained 
via fax or post from the involved hospital.  
In case of death as an event, the details were obtained from the 
medical records, death certificate, post mortem report, coroner’s office 
or GP surgery.  
All events were adjudicated by the principal investigator and me before 
being called as a study end point. All the data obtained was uploaded 
on to an excel document for analysis and recording purposes. 
 
3.11 Statistical analysis 
The normal range for OT and LT was established from healthy 
volunteers. The required sample size for the study was calculated 
based on the Cox Proportional hazards (PH) prognostic model. On the 
  
[ S u m e e t  S h a r m a ]  
 
Page 95 
basis of earlier work (96) in patients acute coronary syndrome and 
normal renal function the unadjusted Hazard ratio (HR) for LT 
dichotomized by 3000 seconds was 2.25 (95% CI= 1.34–4.7). 
Based on the assumption that around 14% MACCE events per year will 
be observed in the ESRD cohort (15,17,35) a sample size of 200 was 
predicted to yield 30 events per year and the final Cox PH model with 
four covariates would provide 5% significance and 80% power (97,98). 
Given 200 patients in the study group and arbitrary selected sample 
size of 100 healthy volunteers, the difference in LT (OT) between these 
groups is classified on the moderate (semi-large) effect size level. The 
Cox PH model was used to assess sample size and Mann–Whitney U 
test used to compare patients and healthy volunteers, with 5 % 
significance and greater than 90 % power. 
Unpaired t-test was used for the normally distributed variables and 
Mann–Whitney U test was used for non-normally distributed variables. 
Two-sided tests were used. Dichotomous variables were compared by 
x2 test or Fisher’s exact test, as appropriate. The uni-variate linear 
regression model was used to assess the relationship between a 
continuous variable (dependent) given a dichotomized variable 
(independent). Where necessary, log transformations were applied. 
Correlations were analysed using Spearman’s rank test.  
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Ability of OT or LT to discriminate between patients with and without 
MACCE was evaluated by receiver operating characteristic (ROC) curve 
analysis. The optimal cut-off was determined by the value providing 
the greatest sum of sensitivity and specificity. The LT level significantly 
discriminated between patients with and without major adverse 
cardiovascular events (MACE) with an area under the curve of 0.67 
(95% confidence interval: 0.55 to 0.69; p < 0.05). An LT >3,000 s 
was identified as the optimal cut point to predict MACE outcome, with 
sensitivity of 60% and specificity of 80%. Suggesting the inclusion of 
LT > 3000s as a risk factor can correctly identify the patients with 
MACCE in 60% of patients (True positive- Sensitivity) and can 
correctly identify 80% of patients with no MACCE (True negative- 
Specificity) 
Kaplan–Meier estimates with log rank tests were used to compare 
survival curves. Uni-variate Cox proportional hazard regression was 
performed on LT divided up into groups of 1000 seconds to investigate 
the relationship between LT and MACCE, and to identify risk factors 
from which a multivariate Cox proportional hazard prognostic model 
was proposed. The hazard proportionality assumption was evaluated in 
the Cox model with scaled Schoenfeld residuals. The test was carried 
out for the uni-variate model including each of the patient variables, 
and its multivariate versions: baseline (age, sex, haematocrit) and 
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extended (age, sex, haematocrit, LT≥3000). In both setups, the hazard 
proportionality assumption was not rejected at p value = 0.05 
significance. 
 
To assess the added predictive ability of LT≥3000 seconds for MACCE, 
net reclassification improvement analysis (99) was performed. For 
chosen risk cut-offs, models do not recognize patients within the low-
risk group (5 %), among patients with and without events.  
 
The effect of interventions (heparin, aspirin, clopidogrel, and dialysis) 
on thrombotic status was evaluated with Wilcoxon signed rank test. All 
tests were two sided and significance was defined as p value < 0.05. 
Analyses were performed with R project for statistical computing 
software (R Foundation for Statistical Computing, Vienna, Austria). 
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Chapter 4: 
Pilot study: Fistula 
Vs. Venous sample 
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4.1 Background 
In ESRD patients, vascular access is important. It is traditional in 
many renal units to check the patients' biochemical parameters pre 
and post HD. The samples are normally taken from the fistula needles 
for convenience and to protect peripheral veins for potential fistula 
formation in the future. There is no consensus in the literature about 
the reliability of platelet function studies in samples obtained from 
sites other than peripheral veins.  
 
4.2 Aim 
Blood sampling and analysis of thrombotic status was a key feature of 
my research study. With this background in mind, a small pilot study 
was done to compare the thrombotic status results in 25 patients with 
samples obtained either from a peripheral vein with minimal 
tourniquet time or from the arterio-venous fistula.  
 
 
4.3 Methods 
The fistula samples were obtained before the start of dialysis at the 
time of needling of fistula. Simultaneous peripheral venepuncture was 
performed on the ante-cubital vein of the opposite limb. Samples from 
both sites were used for thrombotic status analysis using global 
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thrombosis test as explained previously. The peripheral venous sample 
was obtained from the non-fistula limb using the ante-cubital vein, 
where possible, and the same technique as described in the methods 
chapter for the main study. Where possible the tourniquet was avoided 
for the peripheral vein sampling and when used the duration was kept 
to minimum. The 18- gauge butterfly needle was used for the 
peripheral venous sample. All the fistula samples were collected 
without the use of any tourniquet and using the standard single needle 
procedure as per the dialysis unit protocol. For most fistula samples 
this was also 18 gauge needle but with no butterfly extension tubing. 
The fistula sample was taken by the dialysis specialist nurse while 
handling the fistula prior to the commencement of the dialysis and 
prior to any heparin administration. No extra punctures were done to 
the fistula for the purpose of this study. 
 
4.4 Results 
The median OT in the sample obtained from the fistula site was 487 ± 
108 seconds. In the same patients the median OT from the peripheral 
venepuncture site was 408 ± 131 seconds (p=ns, OT values with 
standard deviation). 
The OT values were not correlated as confirmed by Pearson correlation 
coefficient of 0.28. 
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The median LT value obtained from the fistula sample was 1049 
seconds compared to 1167 seconds from the peripheral venepuncture. 
Again the Pearson r value did not show any correlation with a 
coefficient of -0.18. This suggested a wide variation in results in the 
samples obtained from fistula compared to the peripheral venous 
sample. 
The data is shown in table 5.1. 
 
Patient 
Number 
OT- Fistula OT-Venous LT- Venous LT–Fistula 
1 
364.7 408.3 1708 937 
2 
373.1 536.5 1119 826 
3 
471.8 577.7 1335 1320 
4 
477 607.7 1149 1746 
5 
603 468 1099 865 
6 
323.6 362.7 1473 1639 
7 
547.7 341.9 806 655 
8 
601.6 322 822 759 
9 
562 421.7 2243 2992 
10 
694.8 518.8 1265 1464 
11 
374.1 325.5 1313 916 
12 
487.8 348 6000 1028 
13 
618 566.6 1036 919 
14 
670 569.2 1660 1581 
15 
487.6 439.3 1124 2874 
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Table 4.1- Table 
showing comparison of OT and LT values obtained from peripheral vein and fistula 
 
4.5 Discussion 
There are few studies comparing blood results obtained from a 
peripheral venepuncture and samples obtained from central catheters 
in dialysis patients. One study compared three different methods of 
blood sampling for INR values in HD patient (100). The INR samples 
were obtained from a peripheral venepuncture site, the central venous 
line, and the arterial bloodline sample port. The peripheral INR sample 
was used as the gold standard. The sample included 33 HD patients 
with patent dialysis central venous lines. Blood samples were drawn 
with a standardized protocol during one HD session from each of the 
three sites. The Pearson correlation coefficient for the peripheral 
16 
469.8 432.3 977 1865 
17 
356.1 283.2 1049 1422 
18 
439.8 103.6 529 1049 
19 
632 401 925 489 
20 
445.3 375.6 1805 1453 
21 
358 376.5 1705 742 
22 
451.4 637.2 6000 660 
23 
506.9 148.3 1129 2259 
24 
523.1 400.2 1167 1627 
25 
647 488.9 6000 800 
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sample versus the central venous catheter line sample was 0.97 (p < 
0.001) and was 0.99 (p < 0.001) between the peripheral sample and 
the arterial bloodline sample. These results suggested that both 
alternative methods are suitable for taking INR samples in HD patients.  
The purpose of this study was to ensure that samples for INR can 
reliably be taken from the central venous catheter since it is 
heparinized between dialysis sessions. The authors here again were 
faced by the same question as I was for my study regarding choosing 
the appropriate site for blood sampling in HD patients. In my study the 
turbulent flow in the fistula can alter platelet function, in theory, thus 
choosing the site for sampling blood was a vital part of my study. This 
has been suggested in other studies of similar design but there are not 
many studies comparing samples obtained from peripheral 
venepuncture to fistula samples. 
In 1983, David et al (101) compared the samples taken from 
peripheral vein to the ones obtained via the arterio-venous fistula. 
When a single-needle system is used, the blood is obtained through 
the arterial limb of the Y cannula, thus avoiding an extra venepuncture. 
The pre dialysis sample is taken immediately after the cannula is 
inserted and the post dialysis sample is taken after the blood lines 
have been disconnected and the venous limb clamped.  In this study 
they compared samples taken from the arterio-venous fistula and 
  
[ S u m e e t  S h a r m a ]  
 
Page 104 
those taken simultaneously from a peripheral vein in the opposite arm. 
The authors, in this study, concluded that post-dialysis concentrations 
should be determined from peripheral vein samples only based on the 
differences found in the results. This study addressed the question of 
whether sampling blood for urea measurement would give similar 
results when blood is drawn from the fistula or from a peripheral vein. 
Any differences will relate to the timing of the samples since urea is 
distributed in 2 pools which take some time to equilibrate. Hence 
sampling from the fistula (blood form central circulation) immediately 
post dialysis will show a lower urea concentration than that taken 
peripherally, which is equilibrated. The reasons for the differences 
seen in my study may be not related to the observations here, but 
nevertheless raise the question about using the appropriate site for 
obtaining samples in HD patients. 
In a very small but interesting study Twardowski et al (102) measured 
platelet counts of 20 patients under regular dialysis with an arterio-
venous fistula in one forearm, from blood samples taken 
simultaneously from the ante-cubital vein, the arterialized vein near 
the site of anastomosis, the femoral vein, and the femoral artery. 
Samples of blood from the fistula and from the cubital vein of the 
opposite limb were taken with and without tourniquet application 
(causing stasis). The highest platelet counts were found in blood taken 
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from the cubital vein without stasis. Platelet counts were identical in 
femoral artery and vein, but were 4.8 and 4.9%, respectively, lower 
than the cubital vein values. Platelet counts from fistula blood taken 
without stasis were 13.7% lower than in the cubital vein. Platelet 
counts were lower when samples of blood were taken with stasis: 
11.2% in the cubital vein, 7.4% in fistula blood. These are important 
findings, especially when studying platelet functions in dialysis patients. 
It has been shown in other studies that shear forces at physiological 
level (1,000–10,000 s-1) can form small transient platelet aggregates by 
development of membrane tethers (103) whereas at higher shear 
rates (>10,000 s-1), which are considered pathological (similar to 
shear rates found in a stenosed vessel) large rolling aggregates can 
develop independently of integrin IIb 3 and platelet activation (85). 
There have been some recent rheological studies showing that platelet 
and vWF modulation by hydrodynamic force is a mechanism for 
activation-independent aggregation that may contribute towards 
thrombotic arterial occlusion (104). This is unlike the findings from 
older studies  which showed that shear stress in excess of 60 dyn/cm2 
can induce vWF binding to GP Ibα, (105) resulting in platelet 
aggregation, but only if activation can occur and αIIbβ3 is fully 
functional (106). Thus as both the fistula flow and tourniquet 
application causes increased shear rates, it can cause the altered  
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absolute platelet count measurement from samples taken from the 
fistula or after tourniquet application, due to platelet clumping. The 
varying shear forces acting on the blood flowing through a fistula and 
after a tourniquet application can result in platelet activation 
independent aggregation as described above and thus potentially 
altering global thrombotic status assessment in such situations. It 
cannot be predicted what exact effects will be observed based on the 
current knowledge as the effects vary with differing shear stress rates. 
As blood sampling was a key feature of my research study it was very 
important to avoid any discrepancy in the results obtained due to 
sample site choice.  
 
4.6 Conclusion  
Although this was a very small sample size, there was clear lack of 
correlation in the results obtained from two different sites in this sub-
study. This could merely be due to lack of adequate numbers or could 
be due to the fact that two operators were involved in obtaining 
individual samples and thus there can be operator variability in 
handling the sample. Also as the peripheral venous sample were 
obtained after tourniquet application it can contribute towards shear 
induced transient platelet aggregation as described in the literature 
and thus affecting the results of the GTT. It is also possible that the 
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different needles used to obtain sample from the two sites contributed 
in the observed results, as the shear forces acting transiently will alter 
platelet functionality differently at variable shear levels.  
This study was done before commencing recruitment for the main 
study and my technique was on a learning curve phase and thus there 
is a possibility that the variation in results could have been partly 
contributed by the lack of consistency in sample handling. The findings 
of this small sub-study cannot be generalised to all patients with 
fistula but due to the differences observed in the GTT values obtained 
via the fistula compared to a peripheral vein, it was concluded that 
fistula blood sample cannot be reliably used to analyse thrombotic 
state of HD patients for the purposes of main study. Thus the 
peripheral venepuncture would be used as the default method as 
described earlier (Chapter2). 
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Chapter 5: 
Results 
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5.1 Introduction 
In this section I will discuss the demographics and the results of the 
main group (HD patients) of the study population. The main population 
of this study were the patients undergoing HD under supervision of the 
Nephrology department of the East and North Hertfordshire NHS Trust 
at their three dialysis units. The main unit is based at the Lister 
hospital in Stevenage and the other two satellite units are based at the 
St. Albans City Hospital and the Luton and Dunstable Hospital. The 
patients were approached and given information and consented 
according to the protocol previously described in chapter 3. The ethics 
approval was obtained as previously described. 
A control group comprising of 100 healthy volunteers was also tested 
using the GTT. This group was not taking any regular medications and 
was matched proportionally for sex and race. The average age in this 
group was 38 ± 11 years. There were 55 males and 45 females in this 
group. Subjects were recruited, through advertisement and direct 
approach, from among hospital staff and from relatives and carers of 
patients attending the outpatient department.  
In total two hundred and sixteen (n=216) HD patients were recruited 
into the study from across the three dialysis units. The majority were 
receiving treatment at the Lister hospital renal unit. All the inclusion 
and exclusion criteria were met as described in the methodology 
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chapter previously (chapter 3). All patients had been on established 
HD for at least three months. 
Blood samples for GTT were obtained from all the participants on the 
day of their dialysis appointment, prior to commencing the dialysis 
treatment for the day.  
 
5.2 Study population demographics 
The average age of the study participants was 64 years, with age 
range between eighteen and ninety years. Out of the two hundred and 
sixteen participants one hundred and thirty eight were males (64 %). 
The majority of the participants were Caucasian (84 %) with 16 % 
non-Caucasians of which 64 % were of south-east Asian origin and 
remainder Afro-Caribbean. Majority of the participants (70 %) had 
hypertension. Approximately, just under a third of patients had 
diabetes (28.7 %) and history of known coronary artery disease 
(28.7 %). A total of 11 % had a documented history of myocardial 
infarction previously.  
About 62 % of the participants were on an antiplatelet agent with 
majority (51 %) taking aspirin and around 11 % taking clopidogrel. 
The other major drug groups in use in the study population included 
proton pump inhibitors (55 %), statins (44 %) and diuretics (41 %). 
Almost the entire group was on erythropoietin (94 %).   
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Apart from the patient details, medical history, list of medications, 
blood test results (biochemistry, dialysis parameters) pre and post 
dialysis weight and blood pressure readings were also recorded from 
the day of the test. The proforma used to collect the data is shown in 
the appendix. All the data was transferred from paper format to 
electronic, anonymised format using the Microsoft excel software. 
The detailed characteristics of the study population are shown in Table 
5.1. 
Table 5.1: Study Population demographics: 
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Baseline Characteristics 
Age, mean (range) 
Male Gender 
Hypertension 
Hyperlipidemia 
Diabetes 
Prior CAD 
Prior CVA 
Prior MI 
LY Dysfunction 
BMI 
Drug History 
Aspirin 
Clopidogrel 
Ace-I 
Statins 
Calcium Channel Blockers 
Proton pump Inhibitors 
Diuretics 
Erythropoietin 
Laboratory Results 
Haemoglobin (g/dl) 
Haematocrit 
Platelet Counts(x109) 
Urea (mmol/l) 
Creatinine (µmol/l) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Calcium(mmol/l) 
64.4±14.8 
 
138 (63.9%) 
 
151(69.9%) 
 
43 (19.9%) 
 
62 (28.7%) 
 
62 (28.7%) 
 
37(17.1%) 
 
25 (11%) 
 
32/152 (21.1%) 
 
26±6 
 
111 (51.4%) 
24 (11.1%) 
73 (33.8%) 
105 (48.6%) 
65(30.1%) 
118 (54.6%) 
89 (41.2%) 
203 (94%) 
 
11.0±1.2 
32.8±3.5 
227±75.4 
20.5±6.8 
732.1±250 
136.5±3.4 
5.0±0.8 
2.4±0.2 
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Phosphate (mmol/l) 
C-Reactive Protein (mg/l) 
Albumin (g/l) 
Bicarbonate (mmol/l) 
Total Cholesterol (mmol/l) 
LDL/HDL Ratio 
Fibrinogen (g/l) 
Parathormone(pg/ml) 
Dialysis Parameters 
Duration Of HD(minutes) 
Kt/V 
Dialysis Vintage (months) 
KRU(ml/min/m2) 
1.6±0.5 
23.7.0±18 
36.0±4.4 
23.6±3.1 
4.1±1.2 
3.5±1.1 
5.7±2.2 
52.3±51 
 
187.9±34.9 
1.3±0.3 
6.3±1 
1.4±1.7 
 
Table5.1: Baseline demographics of the main study population. n=Number, CAD= 
Coronary artery disease, PVD=Peripheral vascular disease, CVA=Cerebrovascular 
accident, MI=Myocardial Infarction, LV=Left ventricle, ACE-Inhibitor= Angiotensin 
converting enzyme inhibitor, PPI= Proton pump inhibitor 
 
5.3 Study Methods 
The main study protocol was designed to assess the thrombotic status 
by using GTT in the HD population and then comparing this to the 
thrombotic status of normal healthy volunteers. The methods used to 
obtain samples are described in detail in Chapter 3. This was followed 
by analysing for any influence of patient demographic profile, medical 
history, medications and dialysis parameters on the results obtained. 
  
[ S u m e e t  S h a r m a ]  
 
Page 114 
The patients were then followed up for study end points, as described 
in Chapter 3 and the events statistically analysed for any possible 
correlation with the results of the thrombosis test GTT. Statistical 
methods used in the study have been defined previously in the 
methodology chapter (Chapter 3, section 3.11). 
 
 5.4 Assessment of thrombotic status in HD patients and 
controls. 
As described in Chapter 3 the sample obtained for GTT analysis 
provides two results, the occlusion time (OT) and the lysis time (LT). 
216 HD patients were sampled to assess the GTT along with the pool 
of 100 normal volunteers. All OT values in this thesis are quoted with 
the standard deviation. 
The median OT observed in the HD patients was 491± 177 seconds. 
This is the time taken for forming the occlusive thrombus. In the 
volunteer group the OT was 378 ± 96 seconds. The OT in the study 
group (HD patients) was significantly prolonged (p= 0.001). Thus HD 
patients make thrombus less quickly than normal volunteers. The 
coefficient of variation for OT was 8 % in normal volunteers and 6 % 
in HD patients, similar to earlier studies using GTT (96).  
 
The LT in the study population was prolonged compared to the healthy 
volunteer group. The median LT was 1820 seconds in the study 
  
[ S u m e e t  S h a r m a ]  
 
Page 115 
population compared to 1053 seconds in the volunteers group (p < 
0.001.) Thus HD patients are less efficient at dissolving a thrombus, 
once formed, than normal volunteers. The coefficient of variation for 
LT was 10 % in normal healthy volunteers and 5 % in HD patients. 
The relation between OT and LT in study population compared to the 
control group is shown in figure 5.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
[ S u m e e t  S h a r m a ]  
 
Page 116 
Figure 5.1: Relationship between OT and LT in the HD group and in 
healthy volunteers 
 
 
 
 
 
 
 
Figure 5.1 Legend: Distribution of (A) occlusion time and (B) lysis time of healthy volunteers and (C) 
occlusion time and (D) lysis time in HD patients. Y-axis shows number of subjects. 
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There was no correlation between OT and LT (Spearman's rank 
correlation coefficient = 0.15). 
The OT both in the study population and the healthy volunteer group 
followed a Gaussian (normal) distribution. The LT on the other hand 
did not follow the Gaussian distribution in either group and in the HD 
patients had a very late second peak, which was not present in the 
control population. 
In the control group none of the subjects had LT≥3000 seconds 
compared with 41.7 % of the study patients. Remarkably, over a third 
(34 %) of the study population group demonstrated markedly impaired 
thrombolytic status with LT ≥ 6000 seconds (second peak). 
To assess the effect of HD on thrombotic status, a subgroup of 20 
patients was tested immediately before starting dialysis and then 
retested 2 hours after finishing dialysis.  
OT was similar in this group both pre and post dialysis with OT value 
of 570 ± 138 seconds pre dialysis and 545 ± 126 seconds  post 
dialysis (p  = 0.368). LT in this sub group was also similar with median 
pre dialysis reading of 1725 seconds compared to post dialysis LT of 
1665 seconds (p value= 0.753). This suggests that the thrombotic 
status was not affected by HD. 
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5.5 Covariate analysis: influence of demographic profile, 
medical co-morbidities and medications on thrombotic status of 
HD patients. 
All patient characteristics and variables including demographics, past 
medical history and baseline blood results were interrogated for effects 
on OT and LT.  
Patients who were taking clopidogrel exhibited longer (less thrombotic) 
OT than those not taking clopidogrel. In patients on clopidogrel the OT 
was 564±179 seconds compared to 482±175 seconds in the non-
clopidogrel takers, giving a p value of < 0.021. This would be as 
expected with an anti-platelet drug. Thus, provided that patients are 
responsive to clopidogrel they should have prolonged OT or a less 
thrombotic tendency. Occlusion time was also directly correlated with 
serum sodium and urea level. OT was also correlated with male gender 
with prolonged OT in male patients compared to the females. This is a 
surprise finding as the thrombotic events are generally more common 
in males; one would have expected to see a prolonged OT in females 
thus offering them some protection from pro-thrombotic events. 
Although the OT was prolonged in males it did not have any effect on 
the study end points and the thrombotic events were not common in 
either gender. This may be due to selection bias as the majority of the 
patients in this study were males (68%- Table 5.1). 
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In the control group of healthy volunteers aspirin significantly 
prolonged OT. The OT pre Aspirin dose was 356 ± 54 seconds 
compared to 530 ± 99 seconds post dose of Aspirin ( p = 0.0001).The 
use of aspirin did not affect LT, with LT of 1043 seconds in the pre 
aspirin phase and vs. 1049 seconds post the dose( p value =0.741). 
Use of clopidogrel also increased OT in the control group with OT 365 
± 54 seconds pre clopidogrel dose and 569 ± 84 seconds post dose (p 
value = 0.001. Again similar to aspirin, clopidogrel usage did not affect 
LT (with LT 1043 seconds pre-dose and 1067 seconds post-dose, p = 
0.731). The prolongation of OT in response to clopidogrel was 
marginally more than compared to the similar response seen 
secondary to aspirin (as given above, p = 0.02).  
 
In the study group lysis time was not affected by age, gender, race, 
co-morbidities like hypertension, diabetes, peripheral vascular disease, 
and history of MI or dyslipidaemia. LT ≥ 3000 seconds was 
significantly associated with history of prior coronary artery disease, 
with patients with CAD demonstrating prolonged lysis time (p=0.042) 
Both of the antiplatelet drugs (aspirin and clopidogrel) did not have 
any effect on the lysis time but LT was significantly prolonged in 
patients using proton pump inhibitors (p<0.001). Although the number 
of patients this affects is very small, we can postulate that this may 
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reflect a possible effect of proton pump inhibitors inhibiting the 
CYP2C19 iso-enzyme, thereby reducing the ability of clopidogrel in 
inhibiting platelet aggregation.  
The global thrombotic status of the HD patients was not affected by 
the low-molecular weight heparin which was administered during the 
previous session of dialysis. GTT samples were taken before 
administration of the low- molecular weight heparin as described in the 
methods chapter. This allowed a gap of at least 48 hours between 
heparin administration and GTT sampling. Furthermore, to make sure 
that the administration of LMWH (48 hours earlier) did not interfere 
with the results anti-FXa level were checked and were undetectable 
(0.0 iu/mL) in all samples checked. 
 
5.6 Study End points 
All the study participants were followed up from the day of blood 
sample collection as described previously. The follow up was done to 
look for occurrence of any primary and secondary end points (end 
points described in detail previously in chapter 3). Briefly, the primary 
endpoint of the study was the occurrence of major adverse 
cardiovascular and cerebrovascular events (MACCE) defined as the 
composite of cardiovascular death, non-fatal MI, or cerebrovascular 
event. The secondary endpoint was the occurrence of peripheral 
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vascular thrombosis including acute ischaemic limb and AV fistula 
thrombosis. 
Follow-up was available in all patients. The minimum duration of 
available follow-up data was for 365 days. The healthy volunteers 
were not followed up. 
There were 12 non-cardiovascular deaths in the study group. Four of 
these were attributable to dialysis withdrawal. These patients died 
either in a hospice or at home after general health decline and 
cessation of RRT on clinical and personal grounds.  Three patients in 
the group died due to bleeding, one patient had hematemesis 
secondary to chronic liver disease and history of hepatitis and two died 
of unspecified gastrointestinal haemorrhage. Two patients died due to 
sepsis (one of these developed it post knee surgery and the second 
one developed sepsis secondary to abscess in scrotum related to 
epididymoorchitis) and one due to pneumonia. One patient developed 
entero-colitis due to Clostridium difficile and subsequently died.  One 
patient was diagnosed with a malignant neoplasm of the colon and 
died during the follow up period. 
 
In the remaining study population a total of 40 study end point events 
were observed, out of which 23 were MACCE events and 17 peripheral 
thrombotic events. (The detailed description individual components of 
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MACCE and classification of peripheral thrombotic is given previously in 
the chapter 3 titled: Methods.)  Out of the 17 peripheral thrombotic 
events 15 were AV-fistula thrombosis (14 in natural fistulae, 1 in an 
AV graft) and two patients had acute ischaemic limbs. 
 
5.7 Survival analysis: Determination of effect of thrombotic 
status. 
Survival analysis was performed to look for any relationship between 
thrombotic status and primary end points of the study (MACCE). This 
demonstrated no relationship between OT and MACCE, with hazard 
ratio of 1 (95 %% CI 0.9976 to 1.002, p= 0.969). On the other hand 
this analysis revealed a strong relationship between LT and MACCE. 
The optimal cut off point correlating with MACCE was LT ≥ 2940 
seconds. This was rounded to 3000 seconds for clinical ease and 
calculation purposes. LT ≥3000 seconds was associated with a 
significantly higher risk of MACCE overall, giving a Hazard Ratio of 
4.25 (95 %% CI 1.57 to 11.46, p = 0.004). This is depicted in figure 
5.2. 
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Figure 5.2: Incidence of events based on dichotomised Lysis Time. 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Legend: LT= Lysis time, MI= Myocardial Infarction, CVA=Cerebro-
vascular event, CVD=Cardiovascular death, PTE=Peripheral thromboembolic events. 
 
The individual events were also analysed for any correlation between 
LT and events. Nonfatal myocardial infarction or cerebrovascular 
events were strongly related to LT with a hazard ratio of 14.28, 95 % 
CI of 1.86– 109.9 and p= 0.01. Peripheral thrombotic events, when 
assessed separately, also were strongly related to LT. The hazard ratio 
of having a peripheral vascular event with LT ≥ 3000 seconds was 
9.08, with 95 % CI between 2.08–39.75 and p = 0.003. 
 
  * 
Nonfatal MI              CVA                       CV D                       PTE 
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The break-down of MACE events and hazard ratios based on LT are 
summarised in table 5.2. 
 
Table 5.2: Breakdown of MACE events and hazard ratio (HR) based on 
LT. 
 
Overall 
n=216 
LT<3000 
n=126 
LT≥3000 
n=90 
HR(CI) p-value 
CV death, MI, stroke 23 (10.6) 5 (4.0) 18 (20) 
4.25 
(1.58-11.46) 
0.004 
MI and stroke 13 (6.0) 1 (0.8) 12 (13.3) 
14.28 
(1.86-109.9) 
0.011 
CV death 10 (4.6) 4 (3.2) 6 (6.7) 
1.75 
(0.49-6.22) 
0.22 
MI 9 (4.2) 0 (0.0) 9 (10.0) - - 
Stroke 4 (1.9) 1 (0.8) 3 (3.3) 
3.57 
(0.37-34.42) 
0.18 
PTE 17 (7.9) 2 (1.6) 15 (16.7) 
9.08 
(2.08-39.75) 
0.003 
  
 
Table 5.2 Legend: CV death = cardiovascular death, MI = Myocardial infarction, 
PTE= peripheral thromboembolic events. HR=Hazard ratio, CI= confidence interval 
 
All non-fatal myocardial infarctions and 15 out of the 17 peripheral 
thrombotic events occurred in those with LT ≥ 3000 seconds. Non-
  
[ S u m e e t  S h a r m a ]  
 
Page 125 
cardiac death was not related to LT. As LT increased, hazard ratio for 
having an event increased up to LT ≥ 3000 seconds (Figure 5.3 and 
accompanying table 5.3). But there was no additional risk of having an 
event beyond the LT of 4000 seconds, possibly because a large 
number of study participants had severely impaired LT (LT≥6000 s, 
Figure 5.3 D).  
 
Figure 5.3: Hazard ratio for Events based on LT divided into 
1000 second intervals 
 
 *= Hazard ratio with confidence intervals in brackets. 
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5.3: Hazard ratio based on LT 
 HR CI 95% 
Lower limit 
CI 95% 
Upper limit 
p value 
LT ≥ 1000 1.59 0.47 5.36 0.075 
LT ≥ 2000 3.07 1.14 8.29 0.001 
LT ≥ 3000 4.25 1.58 11.46 0.000 
LT ≥ 4000 2.45 1.04 5.79 0.003 
LT ≥ 5000 2.78 1.18 6.56 0.005 
Legend: LT =Lysis time, HR=Hazard Ratio, CI=Confidence interval  
 
LT is therefore associated with an increased risk of having thrombotic 
events (events defined as described in the study methods previously) 
and prolonged LT is representative of impaired endogenous 
thrombolytic status. Thus it is logical to conclude that impaired 
endogenous thrombolytic status (represented by prolonged LT) was a 
very strong predictor of MACCE. This is shown by the Kaplan-Meir 
survival analysis estimates to look at the probability of event free 
survival in the study population based on the observed lysis time. 
Figure 5.4 shows the Kaplan-Meir curves. 
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Figure 5.4: 
 
Legend: Kaplan–Meier curves showing probability of event-free survival in end-stage 
renal disease based on lysis time. Thrombolytic status was strongly predictive of 
major adverse cardiovascular events. 
 
A uni-variate analysis was performed using all the patient 
characteristics and medication history as summarised in table 5.1 to 
look for any relation between these variables and the occurrence of 
MACCE. This model showed that only the following variables were 
related to MACCE: serum calcium (p value = 0.038), (log) CRP (p 
value = 0.04), and haematocrit (p value = 0.013). There was a 
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negative relation between use of diuretic treatment and MACCE (p 
value = 0.044). 
Regression analysis was performed using a back-step model selection 
procedure, the following three variables were then entered into the 
baseline multivariate Cox proportional hazard model: haematocrit (HR 
= 0.87, 95% CI = 0.78–0.97, P = 0.015), and two traditional risk 
factors, namely age (HR = 0.999, 95% CI = 0.97–1.03, P = 0.944) 
and male sex (HR = 1.24, 95% CI = 0.5–3.03, P =0.645). 
None of these basic covariates were correlated either with LT or its 
dichotomized version, which would have increased the standard error 
of the hazard ratio in the Cox proportional hazard model. 
Multivariate Cox proportional hazard analysis including the baseline 
covariates showed that LT ≥ 3000 seconds remained strongly 
associated with MACCE after adjustment for the baseline risk factors 
(HR = 4.37, 95% CI = 1.58–12.12, P = 0.005). Table 5.4 shows the 
Hazard ratio obtained after adjustment for haematocrit, age and sex to 
LT ≥ 3000 seconds. 
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Table 5.4: Table showing adjusted hazard ratio based on LT. 
Adjusted for haematocrit, age and sex. 
 
 
Legend: CV death = cardiovascular death, MI = Myocardial infarction, CVA = 
cerebro-vascular accident,   PTE= peripheral thromboembolic events. HR=Hazard 
ratio, CI= confidence interval 
 
Overall n=216 
n (%) 
HR(CI) p-value 
HR(CI) 
Adjusted 
p-
value 
 
CVD, nonfatal MI, 
CVA 
23(10.6) 
4.25 
(1.58-
11.46) 
0.004 
4.37 
(1.58-12.12) 
0.005 
Nonfatal MI and 
CVA 
13(6.0) 
14.28 
(1.86-
109.90) 
0.011 
15.76 
(2.00-124.06) 
0.009 
CVD 10(4.6) 
1.75 
(0.49-
6.22) 
NS 
1.64 
(0.44-6.15) 
NS 
 
Nonfatal MI 
9(4.2) - -   
CVA 4(1.9) 
3.57 
(0.37-
34.42) 
NS 
4.89 
(0.46-51.4) 
NS 
 
PTE 17(7.9) 
9.08 
(2.08-
39.75) 
0.003 
10.81 
(2,45-47.68) 
0.002 
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This baseline model (age, sex, haematocrit) was then extended by 
including LT≥3000 seconds to give the final predictive model. After 
this, of all the baseline model covariates, only haematocrit remained 
significant in the extended model adjusted for age, sex, and LT (HR = 
0.89, 95% CI= 0.79–0.99). 
 
Receiver operating characteristic (ROC) curve analysis indicates an 
improvement in the area under the curve with the extended model 
with borderline significance (DeLong test Likelihood ratio test p value 
= 0.058) indicating the usefulness of net reclassification improvement 
analysis, as ROC may not be sensitive enough to detect the new 
marker improvement (107). 
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Figure 5.5: Receiver operating curves for (A) occlusion time and (B) lysis time 
and (C) receiver operating curve analysis showing improvement of the prognostic 
model by adding LT ≥ 3000 s. Lysis time significantly discriminated between patients 
with and without major adverse cardiovascular events.  
 
Figure Legend: AUC= area under the curve. 
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5.8 Reclassification 
Reclassification analysis was performed on the previously mentioned 
baseline model with respect to the extended model (which included LT). 
This showed that adding LT to the baseline risk factor model improves 
risk stratification of patients with ESRD in terms of cardiovascular risk. 
Inclusion of LT≥3000 seconds in the model containing three baseline 
predictors (haematocrit, age, sex) significantly added to the model 
effectiveness (net reclassification improvement = 0.61, p value < , 
0.001) leading to improvement in reclassification mainly of non-event 
patients. 
 
The analysis is done with respect to the arbitrary 5 and 20 % cut off 
points of chance of having an event (risk cut-off levels). This divides 
the patients in to three risk categories, low (less than 5 %), medium 
(between 5 and 20 %) and high risk (more than 20 %). For chosen 
risk cut-offs, models do not recognise patients within the low-risk 
group (<5%), among the patients with and without event. 
 
The extension of the baseline model leads to the improvement in 
reclassification of the group of patients with no events, explained in 
figure 5.6 and accompanying table 5.5. The model extended by 
LT>3000 reclassifies 62 (57.9 %) of the high-risk group (>20 %) 
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patients to the mid-risk group (> 5 % and <20 %), and 3 (4.4 %) 
from the mid to the low-risk group.  
Both models roughly agree about the patient group with events within 
the high risk group (87.5%). The extended model reclassifies 5 of 
them (62.5%) from the medium up to high risk group. 
 
Optimal risk cut-offs 
The results obtained, however, depend on arbitrarily chosen risk cut-
off levels. The net-reclassification analysis applied backwards allows 
finding the cut-off which provides the optimal (smallest p-value) 
reclassification. The new risk cut-offs are 13 and 43%, with NRI= 0.61 
(p value < 0.001). Figure 5.6 shows the reclassification done with 
respect to these optimal points. 
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FIGURE 5.6: RECLASSIFICATION PLOT FOR BASELINE AND EXTENDED 
MODEL  
Legend: Reclassification plot for baseline and extended models. The risk cut-offs are arbitrary values of 5 
and 20% (dotted lines). A= patients with events and B= patients with no events. Extending the baseline 
prognostic model (age, sex, haematocrit) by inclusion of LT≥3000s helps reclassify patients without 
events (see text). 
Figure A:  
A1: region where the extended model correctly reclassifies the patients with event with respect to the 
baseline model from the medium to high-risk group. 
A2: region where the extended model correctly reclassifies the patients with no events with respect to the 
baseline model from the high to medium risk group. 
Figure B 
A1: region where the extended model wrongly reclassifies the non-event patients with respect to the 
baseline model from the medium to high-risk group. 
A2: region where the extended model correctly reclassifies the non-event patients with respect to the 
baseline model from the high- to medium risk group. 
A3: region where the extended model correctly reclassifies the non-event patients with respect to the 
baseline model from the high- to mid-risk group. 
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Table5.5. Accompanying table to Figure 5.6 showing that the 
extended prognostic model including LT≥3000s helps reclassify the 
patients without MACE events from high to medium risk group, and 
from medium to low risk group.  
 
NO 
EVENT 
     
  Extended model  
 Risk groups Low Medium High Total 
Baseline 
model 
Low 0 2(100%) 0 2 
Medium 29(22%) 76(58%) 27(20%) 132 
High 0 33(56%) 26(44%) 59 
 Total 29 111 53 193 
EVENT      
Baseline 
model 
Low 0 0 0 0 
Medium 0 4(40%) 6(60%) 10 
High 0 2(15%) 11(85%) 13 
 Total 0 6 17 23 
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Chapter 6: 
Sub-study: 
Peritoneal Vs. 
Haemodialysis 
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6.1 Background 
ESRD has been associated with profound clinical effects ranging from 
thrombosis to bleeding complications. RRT can be provided by different 
modalities, including HD, PD and renal transplantation. There is no 
consensus regarding the physiological or clinical outcome differences 
seen in these people based on the modality of RRT received. There is 
evidence suggesting that overall patient survival is similar for 
peritoneal and HD patients but that important differences do exist 
within select subgroups, particularly those subgroups defined by age 
and the presence or absence of diabetes. (108). An earlier study (108) 
compared 6 registry data based studies and 3 prospective cohort 
studies conducted in USA, Canada, Denmark and Netherlands. The 
authors also compared these studies to the US medi-care data. 
Differences in results between these 9 studies can be attributed to the 
degree of case-mix adjustment carried out and to the use of different 
subgroups when comparing mortality between HD and PD.  After 
accounting for these differences, the authors found a remarkable 
degree of synergism in results between the registry studies and, to a 
lesser degree, the prospective cohort studies. PD was generally found 
to be associated with equal or better survival among non-diabetic 
patients and younger diabetic patients in all four countries. However, 
among older diabetic patients, results varied by country.  
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The Canadian and Danish registries showed no difference in survival 
between PD and HD among older diabetics while in the US, HD was 
associated with better survival for diabetics aged 45 and older. In 
another registry, the investigators compared mortality between 
patients treated with PD and HD (including home HD) using data from 
over 25000 patients in the Australia and New Zealand Dialysis and 
Transplant Registry. Overall mortality rates were significantly lower 
during the 90 to 365 day period among those on PD at day 90 (HR 
0.89; 95% CI 0.81 to 0.99; P < 0.001). This effect, however, varied 
with the presence of comorbidities: younger patients without 
comorbidities had a mortality advantage with PD treatment, but other 
groups did not. After 12 months, the use of PD at day 90 was 
associated with significantly increased mortality (HR 1.33; 95% CI 
1.24 to 1.42; P < 0.001). These data suggest that the effect of dialysis 
modality on survival for an individual depends on time, age, and 
presence of comorbidities. Treatment with PD may be advantageous 
initially but may be associated with higher mortality after 12 months. 
These findings from the registry could be attributable to confounding 
factors which persist despite statistical corrections. For example, it has 
been postulated that acutely ill patients who start dialysis urgently are 
at high risk of death and they are treated predominantly with HD. This 
could induce selection bias in the comparison of mortality between HD 
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and PD patients. Couchoud et al (109), found a significant difference in 
mortality between “unplanned” and “planned” HD starts and suggested 
that comparing PD and HD after removing unplanned HD starts would 
likely provide a more balanced estimate of the effect of modality 
choice on survival in elderly patients. Similarly it has been suggested 
that other techniques involved in providing dialysis are frequently not 
taken into account when doing such comparisons (110). In many 
survival comparisons, the type of vascular access used for HD is not 
included in the analyses. For instance Perl et al. (111) recently showed 
that type of vascular access plays an important role in the relationship 
between dialysis modality and mortality. They found in this registry 
based, Canadian cohort, observational study that starting HD with a 
central venous catheter was associated with higher early mortality risk 
when compared to patients starting dialysis with a functional AV fistula 
or AV graft. The 1 year mortality in the graft/fistula group was similar 
to the PD patients. These relationships persisted over a 5-year follow-
up period. As this study was a non-randomized observational study, so 
there are many confounding factors that can account for the results.  
Nevertheless, despite the possible bias and lack of any randomized 
trail data, the differences in mortality based on dialysis modality are 
variable and three factors, namely DM, age, and co-morbidity, have 
repeatedly been found to modify the effect of treatment modality on 
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patient outcomes.  Historically, it has been felt that the slower loss of 
residual renal function and urine output in PD patients may provide an 
early survival advantage and that the loss of ultrafiltration capacity 
may complicate volume control in PD patients, leading to an increased 
risk of death with time on therapy (112). Whether these findings are 
due to increased cardiovascular or thrombotic complications secondary 
to change in global thrombotic status is unknown. 
There have been small studies in the past comparing the platelet 
function and thrombotic status in patients on PD to HD patients but 
there is still lack of consensus on this issue. In a small study (113) 37 
normal healthy subjects , 18 patients with mild chronic renal failure, 
15 patients with advanced renal failure, 18 HD patients and 11 PD 
patients were included and the expression of platelet surface receptors 
GPIb (the receptor for vWF) and GPIIb/IIIa (the receptor for 
fibrinogen) was investigated with monoclonal antibodies CD42 and 
CD41 flow cytometry. The authors found a negative correlation 
between serum creatinine and the expression of glycoprotein GPIb. 
The defect was not corrected by HD and/or PD. On the other hand HD 
and PD had different impact on the expression of GPIIb/IIIa 
glycoprotein with PD seemingly favourably restoring normal values of 
the expression of this membrane protein. Theoretically this data could 
be correlated to the better biocompatibility of the PD and to more 
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favorable clinical outcomes in terms of accelerated atherosclerosis and 
athero-thrombotic complications in patients with ESRD.  
 
6.2 Aim 
The aim of this sub-study was to establish any differences in global 
thrombotic status of ESRD patients based on the dialysis modality 
used for RRT. 
 
6.3 Methods  
Patients on PD under supervision of the Lister Hospital were 
approached for participation in the study on the day of their out-
patient appointment at the hospital. They were provided information in 
same manner as described in the chapter 2 for the HD patients. They 
were re-approached for consent and sampling on the day of their next 
clinic appointment. Blood samples were collected for thrombotic status 
analysis from peripheral veins as described in chapter 2. 
Twelve peritoneal patients were enrolled in this sub-study.  The 
majority of the patients in the unit at the time of the study were on HD 
and only around 30 were on PD. All of them were approached for 
participation but only 12 agreed. The blood samples for GTT were 
collected using the same technique as described earlier for the main 
study population. Patients were approached at the time of their clinic 
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appointment and study was discussed and relevant paper work, 
including the patient information sheet (appendix) and consent form 
provided. These patients were then re-approached at the time of their 
next clinic follow up appointment and, if they agreed, were recruited 
into the study. All patients had the sample taken in the morning at the 
time of their outpatient clinic appointment. 
The 12 PD patients were compared to 216 HD patients. Blood samples 
were tested with the GTT to obtain the OT and LT values as described 
in the methods Chapter 3 earlier.  Unlike the HD patients the PD 
patients were not followed up for any clinical events and the role of the 
study was just to compare baseline thrombotic status of patients 
receiving different dialysis modalities. 
 
6.4 Results 
All patients had been on PD for at least 3 months with average 
duration being 22 months. The PD patients were younger compared to 
the HD patients with the average age in PD patients being 52 ± 15 
years compared to 64 ± 14 years amongst HD patients. The OT in 
patients receiving PD was 419 ± 134 seconds and the median LT was 
2561 seconds. The thrombotic status in the PD patients in this 
subgroup study did not differ significantly from patients on HD (OT 
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419±134 seconds vs. 491±177 seconds, p value= 0.672 and LT 2561 
vs. 1820 seconds, p value= 0.574). 
 
6.5 Discussion 
The pathogenesis of bleeding in uremic patents is considered 
multifactorial. It has been attributed to platelet dysfunction particularly 
platelet-platelet and platelet-vessel wall interactions. RRT has helped 
reduce bleeding related complications, but the risk persists. 
Abnormalities of blood coagulation and fibrinolysis predispose uremic 
patients to a hypercoagulable state carrying the risk of cardiovascular 
thrombotic events and thrombotic complications such as thrombosis of 
the vascular access. There are differences in the measurement of 
various haemostatic parameters in patients with ESRD concerning 
treatment with either HD or continuous ambulatory PD. There have 
been small studies in the past showing significant differences between 
totally aggregated platelets, reversibly and irreversibly aggregated 
platelets, the percentage of large platelets (p<0.0001) and the 
average number of platelets per aggregate (p<0.001) in dialysis 
patients compared with control persons. However, no differences have 
been found between HD and PD groups, or the duration of dialysis 
treatment (114). 
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On the other hand there have been some studies, albeit in small 
groups and dating from periods when HD was more bio-incompatible, 
showing that renal transplantation and PD improved platelet function, 
while the HD procedure itself impaired platelet function (115). 
Damage to blood vessel walls exposes tissue factor-containing cells 
from underlying cell layers to the bloodstream. Tissue factor (TF) is 
then able to bind in the presence of calcium to Factor VII, the calcium 
forming a bridge between TF and FVII. This sets off an extracellular 
cascade involving sequential serine protease activations leading to 
conversion of prothrombin (II) to thrombin (IIa), which converts 
fibrinogen (Fgn) to fibrin, leading to fibrin deposition and the activation 
of platelets to form thrombus (Figure 6.1). 
 
Tissue factor pathway inhibitor (TFPI) is a potent anticoagulant protein. 
TFPI down-regulates the initiation of coagulation by inhibition of 
FVIIa/TF/FXa and blockage of TFPI enhances FXa and thrombin 
generation. Decreased TFPI activity contributes to the development of 
both arterial and venous thrombosis and has been implicated in the 
thrombotic events occurring in women using oral contraceptives and in 
patients with paroxysmal nocturnal haemoglobinuria.  
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Figure 6.1*: Arterial thrombosis involves the formation of platelet-rich clot that 
forms after rupture of atherosclerotic plaques and exposure of procoagulant material 
such as lipid-rich macrophages (foam cells), collagen, tissue factor, and/or 
endothelial breach, in a high shear environment. TM = thrombomodulin; II = 
prothrombin; IIa = thrombin; Fgn = fibrinogen; TF = tissue factor. 
* Adapted from Wolberg AS, Aleman MM, Thrombosis Research 2010 Apr; 125 Suppl 
1:S35-7 
 
 
Recently in a single center cross sectional study, it was observed that 
compared with healthy control subjects, patients on both forms of 
dialysis showed pro-thrombotic coagulation protein profiles.  
In this study the tissue-factor pathway was markedly elevated in both 
groups, but PD was associated with significantly greater concentrations 
of tissue factor (p= 0.0056) and tissue-factor pathway inhibitor (p= 
0.0138). Similarly, compared with patients receiving HD, patients on 
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PD had greater concentrations of fibrinogen (p=0.0325), which 
corresponded with platelet hyper-function as measured by platelet 
contractile force and clot elastic modulus (p=0.003 and 0.017 
respectively), compared with HD patients using thromboelastography. 
The high level of TFPI might thus counterbalance the increased activity 
of factor VII in uraemia, and may be seen as a defence mechanism 
against a hypercoagulable state.The authors, thus, concluded that 
compared with HD patients, patients on PD appear to have a more 
pro-thrombotic profile (116). Given PD patients are exposed to 
glucose-based dialysate; it is believed that they can experience 
metabolic derangements. Theoretically, this exposure should create a 
more prothrombotic environment than that occurs in HD patients.  
Thus, currently there is lack of any consensus or large studies 
evaluating the platelet function in patients receiving RRT with PD 
compared to HD; in particular there are no studies which have 
assessed global thrombotic status, of patients in ESRD treated with 
different modalities of renal replacement. 
 
6.6 Conclusion 
The thrombotic status in the PD patients in this subgroup study did not 
differ significantly from patients on HD. An important limitation was 
the small sample size. This study nevertheless provides an insight into 
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the possible similarity of thrombotic status in ESRD patients 
irrespective of dialysis modality. The timing of blood sampling was 
different in the groups and also in the same group due to variable 
dialysis schedule and clinic appointments.  As it has been shown in 
previous studies that spontaneous fibrinolytic activity in blood shows a 
sinusoidal variation within a period of 24 hour (117), it is possible that 
this might have affected the results.  No co-morbidity data or drug 
history was collected in the PD group which certainly could have 
influenced on the results.  The patients on PD were not followed up for 
clinical events and thus no conclusion can be drawn regarding the 
association between impaired endogenous thrombolytic ability in this 
sub group and cardiovascular or peripheral thrombotic events. 
Nevertheless based on this small pilot study it can be speculated that 
the modality of renal replacement does not affect the thrombotic 
status in ESRD. Further work though is necessary to confirm these 
findings. 
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Chapter 7: 
Sub-study: Comparison of 
thrombotic status in patients 
post renal transplant and 
those on haemodialysis 
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7.1  
Background 
Renal transplant is one of the three modalities used for RRT in ESRD 
patients. Most dialysis patients would choose to receive a kidney 
transplant if possible with very few patients who are receiving 
intensive HD opting against transplantation and choosing to remain on 
dialysis. There are no randomized trials directly comparing 
transplantation to intensive HD. Database and prospective 
nonrandomized studies support a number of conclusions. Compared to 
conventional HD, survival appears to be better with either 
transplantation or intensive HD (118). Conventional maintenance HD 
patients typically receive three sessions per week, each lasting 2.5-5.5 
hours. Recently, the uptake of more intensive HD (>5.5 hours, three 
to seven times per week) has increased. Survival appears to be similar 
between intensive HD and deceased donor kidney transplantation, but 
the best survival is reported with live donor transplantation. Secondly, 
people with a kidney transplant or receiving intensive HD report a 
higher quality of life than people on conventional HD (118). Finally, 
renal transplantation is more costly in the first year, but after about 2 
years should be less costly than any form of HD (98). 
Despite RRT, the increased risk of thrombotic events persists in 
patients with ESRD. A number of observational studies suggest that 
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CVD is more common in renal transplant patients than in the general 
population. 
Cardiovascular events develop at annual rate of 3.5% to 5%, putting 
kidney recipients at a 50-fold excess (119) compared to the general 
population. Pre-transplant CVD is a well-established risk factor for 
post-transplant CVD and cardiovascular mortality. In addition, post-
transplant dyslipidaemias, (120) hypertension, (121) allograft 
dysfunction, delayed or slow graft function and post-transplant 
erythrocytosis (122) are some of the more specific factors that 
increase cardiovascular risk in renal transplant recipients as compared 
to the general population. Apart from the traditional risk factors in pre-
transplant state, the non- traditional risks factors like the renal 
allograft dysfunction, proteinuria, anemia, moderate 
hyperhomocysteinemia and elevated serum C-reactive protein 
concentrations, each dependently confer greater risk of CVD morbidity 
and mortality in the post-transplant period (123) . 
 However, there is insufficient evidence to show whether undergoing 
renal transplantation reduces the risk of future cardiovascular or 
thrombotic events in these patients compared to dialysis patients. 
Renal transplantation aims to normalise renal function and thus reduce 
the risks associated with ESRD. It is well known that the renal function 
normalisation is very variable post-transplant and pre-transplant 
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disease recurrence contributes to future cardiovascular risks in 
transplant recipients (124). It may also be the case that by the time 
transplantation is performed; risk factors have been so prevalent that 
chronic inflammation and atherosclerosis is already widespread and 
irreversible. 
 
7.2 Aim 
The aim of this sub-study was to investigate whether there are 
differences in the global thrombotic status of ESRD patients receiving 
HD compared to ESRD patients who have received renal 
transplantation (with functioning transplanted organ). 
 
7.3 Methods  
Renal transplant patients under supervision of the Lister Hospital were 
approached for participation in the study on the day of their out-
patient appointment at the hospital. They were provided information in 
same manner as described in the chapter 3 for the HD patients. They 
were re-approached for consent and sampling on the day of their next 
clinic appointment. 
Blood samples were collected for GTT analysis from a peripheral vein 
as described in chapter 2. Forty renal transplant recipients were 
enrolled in this sub-study. The samples were collected during the day 
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time while the patients attended their out-patient appointment. Due to 
the clinic schedule all patients were sampled between 14:00 – 17:00 
pm. OT and LT values were obtained to assess the global thrombotic 
status of these patients using the global thrombosis test as described 
previously in chapter 3. These patients were then compared with the 
216 HD patients who formed the part of the main study group. A 
comparison was also made to the patients receiving PD.  
 
7.4 Results 
The average age of the transplant recipients was younger compared to 
the patients on HD. The mean age in this group was 50 ± 14 years 
(compared to 64 +/- 25 years in the HD group). The OT of the renal 
transplant patients was 422 ± 130 seconds. This is very similar to the 
results in the main study population where the OT was 491± 177 
seconds or the PD patients with OT of 419±134seconds. The median 
LT in the transplant recipients was 2071 seconds compared to 1820 
seconds in the main study group (p=ns) and 2561 in the PD group 
(p=ns). 
The global thrombotic status of the renal transplant recipients as 
assessed by GTT was similar to that of patients receiving HD or PD. 
 
 
  
[ S u m e e t  S h a r m a ]  
 
Page 153 
7.5 Discussion 
Despite functioning transplants, renal transplant recipients are at an 
increased risk of thromboembolic events as a consequence of pro-
thrombotic clotting and fibrinolytic abnormalities. This hypercoagulable 
state is, to an extent, associated with immunosuppressant drugs 
required by these patients as they tend to induce endothelial damage 
or augment platelet aggregation.   
In a small study assessing the effect of immunosuppressive drugs on 
platelet function post renal transplantation, soluble P selectin levels 
were measured and platelet aggregation studies performed using a 
whole blood platelet lumi-aggregometer in 40 renal transplant patients. 
P-selectin is a constituent of the platelet granule membrane that is 
transported to the platelet surface after stimulation, and acts as a 
ligand to generate pro-inflammatory and pro-coagulatory platelet-
leukocyte aggregates. Patients were divided in two groups based on 
the use of immunosuppressive agents, in group 1 (n = 24) were 
patients treated with cyclosporine, and group 2 (n = 16) had patients 
treated with tacrolimus. Effects were compared with those in control 
groups of hypertensive subjects and healthy subjects. P-selectin levels 
were appreciably higher in cyclosporine-treated patients, and 
statistically significant differences were observed compared with those 
of tacrolimus-treated patients (p < 0.05), hypertensive subjects 
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(p < 0.01), and healthy subjects (p < 0.05). The authors concluded 
that cyclosporine-treated renal transplant patients show enhanced 
platelet activation (125).  It has been shown in previous in-vitro 
studies that cyclosporine enhances platelet aggregation and ADP-
induced platelet TxA2 release (126).  The immunosuppressive regimens 
per se can cause or worsen hyperlipidemia, hypertension, anemia and 
diabetes, each of which may in turn hasten the progression of CVD 
(125).  
In a small study examining the blood coagulation, fibrinolytic, and 
inhibitory systems in post renal transplant patients, plasma antigen 
concentrations and activities of various proteins in the above pathways 
were measured. Significant elevations of factor IX activity, von 
Willebrand factor (vWF), D-dimer, protein C and tissue type 
plasminogen activator (t-PA) levels were found in these patients 
compared with normal healthy controls. In addition, the patients 
receiving cyclosporine showed a significant elevation of alpha 2-
macroglobulin activity and patients on azathioprine showed a 
significant reduction in factor XII activity when compared with the 
normal controls. It was concluded that transplant recipients treated 
with long-term cyclosporine and prednisone exhibited significant 
elevation of plasma vWF, D-dimer and protein C concentrations. In 
addition, transplant recipients, irrespective of immunosuppressive 
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used showed increased plasma concentrations of D-dimer t-PA 
suggesting in vivo thrombin generation, fibrin formation and 
degradation (127). 
 
Platelet function studies have shown that the numbers of activated 
glycoprotein (GP) IIb/IIIa receptors increased in renal transplant 
patients treated with cyclosporine (128). 
 
There is a significant body of evidence suggesting that renal transplant 
is associated with impaired fibrinolysis. There are several factors 
affecting fibrinolysis in transplant patients. The predominant long-term 
change is hypo fibrinolysis secondary to excessive plasminogen 
activator inhibitor-I (PAI-I).  Steroid and cyclosporine mediated 
immunosuppression plays a role in increase plasma PAI-1 levels in 
transplant patients most likely due to metabolic derangements like 
insulin resistance and dyslipoproteinemia and also genetic factors 
(129). 
 
In a recent, single centre study it was seen that the use of an m TOR 
inhibitor (mTOR-i) everolimus was associated with significantly higher 
levels of vWF, prothrombin fragments, thrombin-activatable 
fibrinolysis inhibitor and plasminogen activator inhibitor-1 compared to 
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a non-mTOR inhibitor based immunosuppressive regimen in renal 
transplant recipients (130).  The higher levels of vWF in the mTOR-i 
group are compatible with either increased endothelial cell activation 
or increased release from activated platelets. Increased levels of 
prothrombin fragment in the mTOR-i group indicate enhanced in vivo 
thrombin formation leading to fibrin generation and platelet activation. 
In addition, increased thrombin generation leads to augmented 
activation of TAFI, which impairs fibrinolysis. Both TAFI and PAI-1, 
inhibitors of fibrinolysis, were increased in the everolimus treated 
patients. This suggests that treatment with an mTOR-i leads to 
increased endothelial activation, thrombin formation and impaired 
fibrinolysis in renal transplant recipients suggesting an increased risk 
of thrombotic events in renal transplant recipients treated with mTOR 
inhibitors. 
Reduction of fibrinolytic factors and activation of platelets may 
therefore shift the balance of the haemostatic system in the post-
transplant patients toward a pro-thrombotic state. Acute graft 
dysfunction can be caused by ischaemic damage or immunological 
injury leading to serious consequences both in the short and long term. 
Early allograft loss, due to acute thrombotic complications, remains a 
constant and proportionally increasing complication of renal 
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transplantation. This is improving with advances in immuno-
suppression therapy.  
 
Thrombotic microangiopathy (TMA) is very rare but serious 
complication of renal transplantation, usually with poor outcome.  It 
involves small vessels and is characterized by intravascular thrombi of 
aggregated platelets leading to thrombocytopenia and variable degrees 
of organ ischemia and anemia, which is due to erythrocyte 
fragmentation in microcirculation. Histologically it includes severe 
microvascular injury characterized by microvascular thrombi (in small 
arteries and/or glomeruli), fibrinoid necrosis of the wall of small 
arteries and, in later stages, severe mucoid to concentric thickening of 
the small arteries. It has been observed that this condition in renal 
allografts is associated with increase of pro-thrombotic factors and 
hypofibrinolysis (131). 
 
In a recently conducted, single centre, nested case control study, it 
was shown that the risk of thrombo-embolic events is eight times 
higher in transplant recipients compared with the general population. 
This study showed that the risk is particularly high in the first year 
after transplantation, but remains elevated even after many years of 
follow-up, and is not fully explained by the greater probability of 
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transplant recipients to be hospitalized (132). This highlights the fact 
that thrombo-embolic events remain a high burden in these patients.  
 
By 3 years after transplantation, nearly 40 % of patients have 
experienced an adverse cardiovascular event (133). Although there 
are robust data on the frequency of risk factors and their contributions 
to CVD in renal transplant recipients, few trials have demonstrated the 
benefit of modifying these risk factors to reduce cardiovascular events 
(134). This suggests there are still unknown mechanisms which could 
be responsible for the increased cardiovascular and thrombotic risks in 
this population despite correction of renal function and modifying the 
traditional risk factors. Although the present study does not have 
sufficient power to draw definitive conclusions, it suggests that 
perhaps the impaired thrombolytic profile in renal transplant recipients, 
similar to the HD population of the main study, might account in part 
for the increased thrombotic events observed in renal transplant 
patients. 
 
7.6 Conclusions 
The global thrombotic status of renal transplant recipients was not 
different to that of the HD or PD patients, suggesting that the modality 
of RRT does not alter the thrombotic status in ESRD.  It has been 
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shown that renal transplantation is associated with hypofibrinolysis, 
and the findings of my study would support this. These suggest 
impaired endogenous thrombolysis in this group. This study did not 
investigate the role of immunosuppression, which is likely a 
contributory factor in the impaired thrombolysis observed and thus 
would limit the generalisation of the results to all transplant recipients. 
The number of patients, in this sub-study, was small and so definitive 
conclusions cannot be made. Further larger studies could be performed 
assessing thrombotic status, using GTT, comparing renal transplant 
patients to those receiving patients receiving other form of renal 
replacement. It would have been interesting to assess the thrombotic 
status in patients with end stage disease before and after renal 
transplantation. Unfortunately, it is difficult to know which patients will 
be transplanted, and thus, it was not possible for me to do this during 
my period of research.  
 
It is important and clinically relevant to firstly establish whether 
transplantation alters thrombotic status, and secondly, to possibly 
monitor or initiate therapeutic measures in patients who remain pro-
thrombotic after transplantation and have an increased risk of 
cardiovascular  and/or vascular thrombotic events. 
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Chapter 8: 
Discussion 
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In this thesis, I have shown that, firstly, ESRD patients have markedly 
impaired endogenous thrombolysis, compared with healthy volunteers 
and secondly, that such impaired thrombolysis is associated with a 
high risk of cardiovascular and peripheral thrombotic events.  
Furthermore, in the subgroup studies it was shown that the thrombotic 
status in ESRD is not influenced by the modality of RRT. Findings were 
similar in HD, PD and transplant patients.  
Some aspects of my findings are not surprising. The fact that there is 
a high risk of thrombotic complications in ESRD patients is to be 
expected. However, what is remarkable is that with a novel, 
physiological, near patient test, we can identify patients at increased 
risk of such complications. 
 
What mechanisms may explain these findings with thrombotic 
status in ESRD? 
It has been observed in the past that CKD is often associated with 
both bleeding tendency and thrombotic events. It is suggested that 
early stages of CKD are typically associated with a pro-thrombotic 
tendency, whereas in its more advanced stage patients have higher 
risk of thrombotic complications but also suffer from a bleeding 
diathesis (135). Although most commonly manifested clinically as 
minor bleeding from skin and mucus membranes, it can frequently 
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occur as gastrointestinal, retro-peritoneal or cerebral haemorrhage, 
and bleeding at other systemic sites too.  
 
Under normal conditions, after a vascular injury, the haemostatic 
mechanism initiates a cascade of coordinated events aimed at sealing 
the injury site (Figure 6.1) Once the endothelium is breached, the sub-
endothelial elements of the vasculature such as collagen (particularly 
types I, III and VI), laminins, and microfibrils are exposed, which 
leads to a change in platelet morphology and provides support for 
platelet adhesion. Several glycoprotein (GP) receptors are present on 
the Platelets, including GP-VI that binds collagen and mediates both 
platelet adhesion and activation at the site of the injury and GPIb-V-IX 
that interacts with collagen bound von Willebrand factor (vWF) and is 
also required for platelet adhesion, (136).  In addition to collagen-
mediated platelet activation, tissue factor (TF) triggers another 
independent and distinct pathway for platelet activation where it forms 
a complex with the active factor VII and initiating a cascade by 
activating factor X, interacting with several enzymes within the 
haemostasis pathways, and ultimately generating thrombin. Thrombin 
in its turn binds to its receptor, protease-activated receptor-1 (PAR-1), 
on platelets and results in the release of adenosine diphosphate (ADP), 
serotonin, and thromboxane A2. Thromboxane A2 is synthesized in the 
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platelets functions as a platelet agonist and as a vasoconstrictor. 
These platelet agonists amplify the signal for thrombus formation by 
activating other platelets and recruiting them to the site of clot 
formation (137). Platelet activation also involves a conformational 
change in GPIIb/IIIa that increases its affinity for fibrinogen and vWF, 
and as such it enhances platelet-platelet affinity. Other substances 
released from platelets that play important roles are, fibronectin, 
which stabilizes platelet aggregates and platelet-derived growth factor, 
which mediates tissue repair physiologically. Termination of the 
process of clot formation involves multiple factors including anti-
thrombin (AT), tissue factor pathway inhibitor (TFPI), and the protein 
C/protein S system. Clot organization and removal is conducted by the 
proteolytic enzyme plasmin.  
 
In addition to the hemostatic mechanisms, there are several 
homeostatic mechanisms that maintain the balance between clot 
formation and bleeding. Tissue plasminogen activator, urokinase 
plasminogen activator, prostacyclin (PGI2), nitric oxide (NO) and 
ectoapyrases are released by normal, functioning endothelial cells to 
maintain a local antithrombotic intravascular surface and degrade ADP 
(138). 
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Another homeostatic mechanism influencing hemostasis is laminar 
blood flow. This is partially influenced by hematocrit and local 
endogenous vasodilators, which modulate blood viscosity and 
vasomotor tone, respectively. A normal hematocrit facilitates the flow 
of red blood cells midstream, which displaces platelets such that they 
are closer to the endothelium; consequently, platelets can react 
quickly to damage to the vasculature (139, 140). The second aspect of 
laminar blood flow that influences hemostasis is vessel radius, which is 
regulated by a number of neurological and chemical mediators 
including, but not limited to, PGI2 and NO. Each of the above areas 
commonly altered in patients with uremia. 
As CKD advances, the pro-coagulant abnormalities persist, but in 
addition, patients start to exhibit platelet dysfunction that typically 
manifests with an increased risk of cutaneous, mucosal, or serosal 
bleeding. Several factors are thought to contribute to platelet 
dysfunction in patients with advanced CKD. In patients with platelet 
dysfunction secondary to uremia, there is thought to be a functional 
defect associated with vWF; either decreased binding affinity for 
GPIb/IX receptors or reduced expression of GPIb/IX receptors on 
platelets (141). Weakened interaction between vWF and GPIb/IX 
receptors alters cytosolic calcium concentrations, resulting in 
decreased production of TxA2 and ADP. One study showed impaired 
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function of platelet aggregation at least partially due to an intrinsic 
GPIIb/IIIa dysfunction and the presence of a putative uremic toxin 
that inhibits fibrinogen binding to GPIIb/IIIa (142). Altered release of 
ADP and serotonin from platelet granules, (143) and faulty arachidonic 
acid and prostaglandin metabolism, (144) have also been reported , 
which all lead to impaired platelet adhesion and aggregation.  
P-selectin is found in the α-granules of platelets. A deficiency in α-
granules could lead to ineffective haemostasis. Two different 
explanations are possible for the deficient platelet α-granules release 
found in CKD. This could be due to depletion of α-granules itself, or 
due to a deficiency in the release of α-granules. 
 
In a study by Bladel et al (145) platelet reactivity was measured using 
flow cytometric analysis. Platelets in whole blood were triggered with 
different concentrations of agonists (TRAP, ADP, CRP) and the platelet 
activation was quantified with staining for P-selectin, measuring the 
mean fluorescence intensity. In this study the authors found that the 
expression of P-selectin on the platelet surface measured as mean 
fluorescence intensity was significantly less in CKD patients compared 
to controls after maximal stimulation with the agonists suggesting 
impaired platelet reactivity.  
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In a similar study, Aggarwal and colleagues found a higher P-selectin 
expression in patients with ESRD receiving HD compared to healthy 
controls after stimulation with a single concentration of ADP 
suggesting an increased reactivity (146). Moal et. al performed a 
similar study in which ADP (200 μM) and TRAP (50 μM) in a single 
concentration were used to stimulate platelets in healthy controls and 
ESRD patients receiving HD. They found a lower P-selectin expression 
in patients compared to controls, indicating reduced platelet reactivity 
in patients with CKD (147). 
 
Thus, there is conflicting evidence in literature with regards to the 
mechanism of haemostasis abnormalities in ESRD. This may be 
attributed to the heterogeneity of the study population, differences in 
methodology of handling platelets and other confounding factors such 
as use of antiplatelet or anticoagulant drugs and other comorbidities.  
 
In addition to haemostatic changes caused by uraemia in the HD 
patient group, HD therapy itself leads to various haemostatic changes. 
These include coagulation cascade activation as a result of contact 
between the dialysis membrane and blood elements, the effect of 
anticoagulants used to prevent coagulation developing due to this 
cascade activation and a decrease in the negative effects on platelet 
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functions of uremic toxins, thought to be eliminated during HD. The 
HD procedure itself may also directly activate tPA, but it is unknown 
whether this activation contributes to an increased bleeding tendency 
in patients receiving it (148). 
Anaemia may also play a pathogenic role in the increased risk of 
bleeding in patients with advanced CKD because correcting it results in 
improved platelet function in this population.  
 
In a large meta-analysis examining the efficacy of antiplatelet agents 
in preserving dialysis access patency, antiplatelet agents appeared 
effective in reducing thrombosis in central venous catheters and AV 
shunts, but not in preventing AV graft thrombosis (149). The bleeding 
risk for patients on dialysis treated with antiplatelet agents appears to 
be related to the prescribed number and type of antiplatelet agents 
used. 
 
In the studies described in this thesis it was observed that the OT was 
significantly prolonged in the ESRD patients on HD compared to the 
healthy volunteers. The prolonged OT in ESRD patients suggests either 
impaired primary haemostasis or reflects the fact that half the patients 
were on at least one antiplatelet agent, or a combination of these 
factors. It is difficult to ascertain the exact pathogenesis of this as the 
  
[ S u m e e t  S h a r m a ]  
 
Page 168 
study was not designed to establish the mechanism. The findings 
suggest that the platelet reactivity is reduced in this group of patients, 
as previously described by others. The effect of anaemia on the 
platelet reactivity could not be established as almost all the patients in 
this study were on erythropoietin and similarly the effect of HD cannot 
be established as all the patient were already on established HD. The 
small subgroups of PD patients and the post renal transplant patients 
did not show any difference in the OT when compared to the main 
group of HD patients. A shortcoming of the study was the lack of a 
control group of patients with earlier stages of CKD which may have 
allowed to distinction between the effects of impaired kidney function 
and the effects of RRT modality on the global thrombotic status.  
 
Prolonged OT signifies delayed thrombus formation in this group and 
logically would imply an increased tendency towards bleeding. The 
study was not specifically designed to look for any bleeding 
complications and may have lacked adequate power to detect this. 
There were only three deaths in the study population secondary to 
bleeding complications. Two of these patients had gastrointestinal 
haemorrhage due to unspecified reasons and the third patient had 
bleeding secondary to chronic liver disease. All three of these patients 
had prolonged OT (661, 687 and 692 seconds) compared to the study 
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population but interestingly the two patients with GI bleeding had LT 
>3000 seconds. Prolonged OT would explain tendency towards 
bleeding but delayed LT would, in theory offer protection from bleeding 
by increasing thrombotic tendency.  This may point towards separate 
mechanisms controlling platelet activation and spontaneous lysis of the 
formed platelet rich thrombus.  However, the study was not designed 
to come to conclusions about the bleeding tendency in these patients 
and these may be just chance findings.  
 
OT was prolonged in the group of patients taking clopidogrel, 
compared to those without clopidogrel. Interestingly Aspirin use 
(approximately just over half the patients were on aspirin {51%} 
compared to only 11% taking clopidogrel) did not have any correlation 
with the OT values in the study. This may suggest that platelet 
aggregation in HD patients is predominantly mediated by ADP- P2Y12 
pathway which is blocked by clopidogrel and thus prolonging OT. This 
is similar to the effect of some uremic toxins. The uremic toxins 
guanidosuccinic acid and phenolic acid lead to platelet aggregation 
defect by inhibiting ADP-induced platelet aggregation (150).  
Alternatively, patients with ESRD on HD may have “resistance” to the 
effects of aspirin.  Aspirin use is standard in patients with coronary 
artery disease and has been shown to reduce the risk of myocardial 
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infarction, stroke, and vascular related deaths in patients with CVD. 
But a significant number of patients prescribed aspirin as 
antithrombotic therapy have major adverse vascular related events 
each year. It is unclear whether these patients simply receive too low 
an aspirin dose, are not compliant, have differing abilities to absorb 
aspirin, or have an underlying genetic disposition that renders aspirin 
ineffective.  Such patients have been labelled aspirin “resistant”. In a 
meta-analysis done in 2007 it has been shown that approximately 
28% of patients taking aspirin can be classified as aspirin resistant. 
Aspirin resistance was higher in patients with previous renal 
impairment (P<0.03) (151). 
OT in this study was found to be inversely related to sodium, urea and 
diuretic use. It is known that the fluid status plays a role in the 
residual renal function and thus the observation here in this study 
could reflect a relationship between the fluid status and OT, although 
the study did not have enough power to establish this. 
OT in this study was not predictive of MACE. This was similar to the 
findings of a similar study involving patients with acute coronary 
syndrome on dual antiplatelet medication (76).  As all the endpoints 
described for the purpose of this study were thrombotic complications, 
a tendency towards delayed thrombosis (prolonged OT) could not be 
used as an explanation for the number of events found in the study 
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and thus suggests that their possibly is another patho-mechanism in 
these patients causing the study endpoints.  
 
Despite the relatively high prevalence of cardiovascular risk factors in 
ESRD, (152) the Framingham risk score projected cardiovascular risk 
in ESRD is similar or somewhat higher than reference populations from 
the Framingham cohort or from the National Health and Nutrition 
Examination Survey (NHANES) III (153).  Even in studies which predict 
higher risk the incidence of CVD observed in dialysis patients or even 
transplant recipients may be underestimated (154).  This emphasizes 
the contributory role of non-traditional risk factors to cardiovascular 
risk in ESRD, which traditional predictive models do not cover.  
 
Although aggressive risk factor modification in CKD with statins, (155) 
angiotensin-converting enzyme inhibitors, (154) and normalization of 
haemoglobin with erythropoietin (156) reduce cardiovascular events, 
(157) thrombotic events continue to occur. Thus, the optimal 
management of cardiovascular risk in ESRD not only requires 
traditional risk factor modification, but also should aim to identify 
newer, previously unknown, risk factors in this complex group. These 
non-traditional risk factors may explain the excess cardiovascular 
events, which are higher than in any other disease state.  
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To define a non-traditional factor as a risk factor, all of the following 
conditions should be met, ideally: (1) biological plausibility as to why 
the factor may promote CVD risk; (2) demonstration that the risk 
factor level increases with severity of kidney disease; (3) 
demonstration of an association between the risk factor and CVD in 
CKD in observational studies; and (4) demonstration in placebo-
controlled clinical trials that treatment of the risk factor decreases CVD 
outcomes. (158).  Although, the first two conditions are met for the 
most part when one considers the non-traditional risk factors there 
remain many gaps in the CKD literature regarding condition 3, and 
particularly regarding condition 4. This is, therefore, an active area of 
interest and research. 
 
In this study, it has been shown that impaired LT is strongly correlated 
with adverse thrombotic events in ESRD, independent of other risk 
factors.  This observation that the endogenous ability to lyse any 
thrombus formed (prolonged LT) in these patients is impaired can 
provide a logical explanation as to why cardiovascular and other 
thrombotic events rate are higher in ESRD patients. But due to the 
non-randomized population and presence of multiple traditional risk 
factors in the patients it could also be a chance observation. 
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The observed cardiovascular events risk in the study is predominantly 
attributable to an increased risk of MI in those with LT≥3000 seconds, 
although it is very unlikely that the LT< 3000 seconds group is 
completely protected from MI. The MACE rate in those with LT< 3000 
seconds was much lower than anticipated and may have contributed to 
the lower than expected significance of the results. Although the 
hazard ratio for MACE is high, the sample size is relatively small and 
the confidence intervals large, thus the results could be due to chance. 
 
 Although studies cannot be directly compared, these findings are 
supported by the prior study in ACS patients, where the same cut-off 
value (LT≥3000 s) was correlated with increased cardiovascular risk 
but imparted a much greater risk in ESRD than in ACS patients (HR 
4.25 vs. 2.5) and LT was more frequently impaired and longer in ESRD 
than in ACS patients (96). 
 
 The distribution of events was not even in the subgroups based on LT 
(Figure 5.2 and table5.2 chapter 5 – results), with a break in events 
between 3000 and 5000 seconds, as there were no events in LT 4000–
5000 seconds group. The reduction in hazard when LT> 4000 seconds 
is likely, at least in part to reflect the uneven distribution of events, 
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with small numbers of patients and even smaller numbers of events in 
these groups. 
 
Components of the fibrinolysis system include t-PA, urokinase, u-PA 
receptor, plasminogen, and inhibitors of plasmin generation such as 
PAI-1 and TAFI (159). During normal haemostasis pro-enzyme 
plasminogen is converted to active plasmin by thrombin. Plasmin 
degrades the cross-linked fibrin into soluble degradation products by 
the tissue-type (TPA) and the urokinase type plasminogen activators. 
It is TPA that is mainly responsible for the dissolution of fibrin formed 
in the circulation. This fibrinolytic system can be inhibited either by 
plasmin through alpha 2-antiplasmin or by specific plasminogen 
activator inhibitors (PAI). The thrombin activatable fibrinolysis inhibitor 
(TAFI) is another important inhibitor of the fibrinolytic system and 
forms a link between blood coagulation and fibrinolysis. Thrombin 
forms fibrin to stabilize the platelet-rich thrombus and also produces 
TAFI to protect that fibrin network. The TAFI circulates as an inactive 
pro-enzyme and becomes activated by thrombin during blood clotting. 
The active form (TAFIa) inhibits fibrinolysis by cleaving off C-terminal 
lysine residues from partially degraded fibrin that stimulate the TPA-
mediated conversion of plasminogen to plasmin. Consequently, 
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removal of these lysines leads to less plasmin formation and 
subsequently to protection of the fibrin clot from breakdown (160). 
 
There have been studies showing increased fibrinogen, plasminogen 
activator inhibitor-1(PAI-1), and reduced tissue plasminogen activator 
in ESRD, (157-158, 161-164). In recent data on fibrin clot properties 
both ESRD (165,166) and thromboembolic coronary events (167, 168, 
169) have been associated with the formation of dense fibrin clots, 
resistant to fibrinolysis. In a study by Undas et al. (170) it was shown, 
by using turbidometric plasma clot lysis, fibrin clot permeability and 
perfusion clot lysis assays, that ACS and CKD patients have higher 
PAI-1 and TPA levels and formed fibrin clots that were less porous and 
more resistant to fibrinolysis, compared to a control group of ACS 
patients with normal renal function. The fibrin clot in CKD patients 
exhibited smaller pore size, larger number of protofibrils per fibrin 
fibre, increased fibre size and clot mass. These studies support the 
findings of reported in this thesis, showing that there is delayed or 
impaired endogenous thrombolytic activity in ESRD as evident by the 
prolonged LT in this group. In this study population, high fibrinogen 
levels (5.7±2.2 g/l) were observed at baseline (table1 demographics- 
chapter 4). The observation of raised fibrinogen level in the study 
group and impaired endogenous thrombolysis is interesting.  Based on 
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epidemiological data, fibrinogen has been associated with increased 
cardiovascular and arterial thrombotic risk, but whether this 
relationship is causal is not established. Recently high fibrinogen levels 
have been linked with resistance to thrombolytic therapy and adverse 
outcome in patients with acute ischaemic stroke (171). Patients with 
high fibrinogen levels displayed worse clinical response and had 2.7-
fold risk to mortality when they received thrombolytic therapy. 
 
In previous studies high fibrinogen levels are shown to lead to a less 
porous and therefore less permeable fibrin clot with thin fibers in 
particular genotypic individuals (172) A tendency to form of tight, rigid 
and space-filling fibrin network structures with small pores has been 
shown to be associated with premature coronary artery disease (173, 
174). 
 
Furthermore, in a murine model, artificial increase in fibrinogen level 
directly promoted thrombosis and thrombolysis resistance, via 
enhanced fibrin formation and stability (175). In this study the 
investigators raised plasma fibrinogen levels in mice via intravenous 
infusion and induced thrombosis by application of shear forces; 
hyperfibrinogenemia significantly shortened the time to occlusion in 
the both high and low shear exposed mice. Using 
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immunohistochemistry, turbidity, confocal microscopy, and 
elastometry it was shown that hyperfibrinogenemia increased 
thrombus fibrin content, promoted faster fibrin formation, and 
increased fibrin network density, strength, and stability. 
Hyperfibrinogenemia also increased thrombus resistance to 
tenecteplase-induced thrombolysis in vivo. 
However, in a transgenic mouse model of hyperfibrinogenaemia, mice 
with high fibrinogen level did not demonstrate accelerated platelet 
thrombus formation in response to injury, compared with wild-type. 
(176). Surprisingly, transgenic mice demonstrated suppression of 
thrombin generation in plasma and activation of the fibrinolytic system. 
Furthermore, alterations in gene expression and coding function, splice 
variants such as the gamma’ splice variation in fibrinogen gene 
transcription, and posttranslational modifications of protein products 
all influence fibrin structure/function and result in more highly cross-
linked and stable fibrin clots, with reduced pore size, that are more 
resistant to lysis (177). 
A study of gamma A/gamma' fibrinogen levels, in patients undergoing 
coronary angiography, has previously shown that gamma A/gamma' 
fibrinogen levels were higher on average in coronary artery disease 
patients than in patients without coronary artery disease, and that this 
association was independent of total fibrinogen levels  (178). 
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In the present study to investigate further the relationship between 
fibrinogen level and impaired endogenous thrombolysis (as measured 
by LT), an in vitro experimental correction was performed to raise 
fibrinogen level and assess the effect on LT. In ten healthy volunteers, 
in parallel measurements, increase in plasma fibrinogen concentration 
in vitro by 1 g/L did not significantly alter LT compared with control 
samples [median LT 1081 (IQR 907–1300) secs and 1297 [1208–
1660] secs respectively, P = 0.06]. Thus increasing fibrinogen 
concentration showed a trend towards enhanced rather than inhibited 
spontaneous thrombolytic activity. These findings in healthy blood are 
similar to previous studies claiming that hyperfibrinogenemia per se 
does not inhibit fibrinolysis (176).  Thus, it is more likely that it is not 
just the elevated plasma fibrinogen concentration per se, but the 
quality of the fibrin clot architecture that determines risk. 
 
It has been shown in previous studies that in ESRD, fibrinogen 
structure and function are altered, making clots more resistant to lysis 
and that the fibrin structure characteristics in the patients are 
associated primarily with the inflammatory plasma milieu rather than 
with level of azotemia (179).  This may be causally related to 
increased thrombotic risk. In a small study it has been shown that in 
patients on chronic HD fibrin clot properties are markedly altered. 
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Fibrin clots from plasma of the patients display significantly reduced 
permeability, faster proto-fibril formation, increased fibre size and clot 
mass, along with decreased susceptibility to fibrinolysis, compared 
with healthy well-matched individuals. These findings indicated that 
clots from HD patients are much tighter than those from controls. 
None of the clot variables showed any association with the duration of 
HD treatment or the cause of ESRD. Although this was a small study, 
there was an association between mortality and reduced clot 
permeability and prolonged LT (180). 
 
This may explain the functional significance of the impaired 
thrombolytic state observed in ESRD and can be possibly used as a 
marker of excess thrombotic event risk in this population. In this study 
I did not compare LT with plasma markers of fibrinolysis, since the 
value of fibrinolysis activity markers is very limited in aiding diagnosis 
and risk stratification in the individual patient. The overall outcome of 
studies looking at prognostic and diagnostic value of fibrinolytic 
markers is highly controversial. The number of negative studies unable 
to demonstrate an association or predictive power is practically equal 
to those reporting a positive association and prognostic value. Even 
some of the positive studies report relative risks that, although 
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significant, are so weak (HR: 1.1 to 1.7) that they indicate only a 
statistical trend but have little practical usefulness (139). 
 
Prolonged LT in the current study was associated with prior CAD but it 
is difficult to say whether it is a causative phenomenon. In a similar 
study lysis time in ACS patients was not related to prior CAD (96). 
Proton pump inhibitor use was related to prolonged LT. This study is 
too small to analyze whether this reflects a possible effect of proton 
pump inhibitors inhibiting the CYP2C19 iso-enzyme, thereby reducing 
the ability of clopidogrel to inhibit platelet aggregation.  
 
Higher serum calcium concentration was associated with prolonged LT. 
This may be functionally important. Ionized calcium (Ca2+) holds 
together the fibrinogen binding receptor glycoprotein IIb/IIIa complex, 
it is essential for agonist-induced conversion of the glycoprotein 
IIb/IIIa complex into the functional fibrinogen receptor, and is 
required for the binding of fibrinogen to its receptor, as well as for the 
coagulation cascade (68). 
C-reactive protein was related to LT suggesting a relationship between 
inflammation and thrombosis. Inflammation biomarkers are strong 
predictors of MI or thrombotic stroke (181) and platelets are known to 
initiate an inflammatory response at the endothelial level by secretion 
of various pro-inflammatory factors and forming a platelet–leucocyte 
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aggregate (PLA) and thus initiating processes pivotal for thrombus 
formation and atherogenesis (182). It is difficult to establish, based on 
this study, whether the relationship between CRP and LT is a cause or 
effect phenomenon in these patients. 
 
Limitations of the study 
The two major limitations of this study are its observational nature and 
the sample size.  The patients enrolled in the study were known to 
have multiple risk factors for cardiovascular or thrombotic events. The 
observational nature of the findings in a high risk group with multiple 
risk factors for the primary end points makes one question the role of 
these known risk factors in influencing the result despite the statistical 
significant correlation between impaired endogenous thrombolysis and 
observed events in this study. 
Since the sample size in the study was relatively small, particularly in 
the sub-studies, a further larger trial would be needed to confirm these 
findings. 
Although we have tried to use appropriate controls in the main study 
and in the sub-studies, there were a few factors which proved difficult 
to control for. For example, age, co-morbidities and aetiology of ESRD. 
Moreover the control group did not have any renal impairment or risk 
factors associated with it.  The main study group patients (HD group) 
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were sampled only once, pre-dialysis, and only a very small group was 
studied pre and post dialysis. The fact that mainly ESRD patients on 
HD were studied means that the results cannot be generalized to 
different modalities of renal replacement or to different stages of CKD. 
More than 90% patients in the HD group received erythropoietin, 
which is known to increase the number of circulating platelets, 
improves platelet function transiently bringing the bleeding time 
towards normal,(183) It has also been shown to have varying effects 
on platelet reactivity and fibrinolysis(184).  It has also been proposed 
that in patients treated with erythropoietin, increased activity of C-
reactive protein, nitric-oxide, and thrombin-activatable fibrinolysis 
inhibitor leads to a fibrinolytic deficit with resultant increase in 
thrombosis (185).  
The effect of antiplatelet medication on LT is not fully established, but 
unlikely to be significant given the findings in a previous study of 
patients with ACS (76) and here in ESRD. It is well known that 
individual patients on antiplatelet therapy have varying response to 
the medications in terms of platelet inhibition and such variation is 
possible in this study but this study was not designed to study effects 
of antiplatelet medications on thrombotic status. Moreover, the effect 
could also vary depending on stage of CKD, modality of RRT and any 
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previous use of such medications in the study population at the time of 
sampling. 
The test used (GTT) is a near patient test and requires meticulous 
sampling, and is subject to error due to effects of tourniquet 
application time or sample transit time, and results can vary 
depending on the site and state of the sample. The timing of blood 
sampling was different in the different groups and also in the same 
group due to variable dialysis schedules and clinic appointments.  As it 
has been shown in previous studies that spontaneous fibrinolytic 
activity in blood shows a sinusoidal variation within a period of 24 hour 
(97), it is possible that this might have affected the results.   
The GTT machine has been used and validated by the manufacturer 
previously and a small study on same patients assessed by more than 
one machine could help to establish the precision of the GTT analysis.   
 The small sub-groups studied, including the PD and the renal 
transplant recipients, were not followed up to investigate the 
relationship between global thrombotic status and any future 
thromboembolic or bleeding events. No data on co-morbidity or 
medication details were collected in the sub-groups which certainly 
could have influenced the findings as groups were not matched for 
comorbidities or medications that could have affected thrombotic 
status. Similarly smoking history, which is a well-known risk factor for 
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thrombotic events, was not collected in this study and it would have 
been interesting and probably relevant to establish a relationship 
between smoking and the GTT results in a high risk population. 
 
Future work 
A larger study assessing thrombotic status in patients undergoing 
different RRT modalities could help establish the effect of RRT modality 
on overall thrombotic status. Furthermore, it would be interesting to 
assess global thrombotic status in patients at different stages of CKD 
repeating the test as the condition progresses, to study the effect of 
progression on thrombotic status. 
 
The role of antiplatelet medications in patients with renal disease and 
the effect of antiplatelet medication on LT are important clinical 
questions. Ideally a prospective study randomizing patients with CKD 
to antiplatelet regimens and assessing the effects of such intervention 
on global thrombotic status would be desirable. Otherwise, larger 
studies would be required where groups matched for CKD status, risk 
factors and medications, but varying with respect to antiplatelet 
medication, could be compared for overall thrombotic status 
assessment. 
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Other medications should also be studied to investigate their effects on 
global thrombotic status, in order to find a potential candidate drug 
that can favourably modulate thrombotic status and may thus reduce 
cardiovascular risk in high risk groups with impaired LT. Such 
medications include oral anticoagulation using vitamin K antagonists or 
novel anticoagulants.  
 
Conclusion 
In summary, this study has identified impaired thrombolysis as a novel 
risk factor in ESRD albeit with limitations, which may have important 
implications for screening and risk stratification. Thrombotic status 
does not appear to be affected by HD. Future studies are required to 
investigate medical therapies to which can improve endogenous 
thrombolysis, and to establish whether such agents may reduce the 
risk of cardiovascular events in these high-risk patients.  
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      Lister Hospital 
Coreys Mill Lane 
Stevenage 
Herts SG1 4AB 
 
Tel: 01438 314333 
 
Queen Elizabeth II Hospoital 
Howlands 
Welwyn garden City 
Herts AL7 4HQ 
 
Tel: 01707 328111 
www.enherts-tr.nhs.uk 
 
REC Ref 09/H0311/25 
 
PATIENT INFORMATION SHEET 
 
You are being invited to take part in a research study. Before deciding whether to take part, you 
need to understand why the research is being done and what it will involve.  Please take time to 
read the following information carefully and discuss it with friends, relatives and your GP as you 
wish. Ask us if there is anything that is not clear or if you would like more information.  Take your 
time deciding whether or not you wish to take part. 
 
National Institute of health research has got an advisory group called INVOLVE (funded by Department of 
health) which provides information on public involvement in NHS, social care, and public health research 
and development (R&D).They Have produced Various publications including a Public Information Pack 
(PIP) titled: How to get actively involved in 
NHS, public health and social care research (2007).This and all of their other publications can be 
downloaded free form there website http://www.invo.org.uk or a free copy can be ordered from –
INVOLVE, Wessex House, Upper Market Street Eastleigh Hampshire SO50 9FD. 
 
Thank you for reading this. 
 
Study Title 
 
Risk of thrombotic events in chronic renal failure (CRF) patients on renal replacement 
therapy (RRT) 
  
 
(The meaning of the title is fully explained below) 
 
 
What is the purpose of this study? 
 
Kidney failure patients despite being on dialysis or having undergone a renal transplant remain at increased 
risk of heart problems. The reason for this is unclear, but likely to be related to either increased platelet 
reactivity, impaired thrombolysis or both. There is currently no way to identify which patients are likely to 
clot off their arteries, and thus whom to target with medication. 
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We propose to do blood tests to identify patients who remain prone to forming clots and/or have impaired 
ability to dissolve clots despite being on dialysis or having received a kidney transplant for kidney failure. 
We will do two blood tests, one before the start of dialysis or receiving a transplant and another after either 
being established on dialysis or becoming stable after the transplant depending on the treatment (dialysis or 
transplant in this case) patients receive. We will then follow patients up for a year and try and correlate 
whether the blood test results can predict who is at increased risk of future heart attacks and stroke and also 
to see if the blood test results were different before and after receiving renal replacement therapy (dialysis 
or transplant) 
If these blood tests can identify which patients at are risks of future events, this group can be targeted in the 
future to individualize and optimize their medication, to reduce their risk of a future heart attack, stroke or 
death. 
 
Why have I been chosen? 
 
You have been chosen to participate since you are suffering with a kidney problem and are at higher risk of 
heart problems than the general population. We are studying why patients with renal failure develop heart 
problems earlier, and whether we can detect who is at risk of future problems. 
 
Do I have to take part? 
 
It is entirely up to you to decide whether or not you wish to take part in this research study, and you should 
not feel under any obligation to take part. Neither your decision to take part, nor your decision to not take 
part, will in any way affect your current or future medical care. 
 
What will happen to me if I take part? 
 
We will take 10 ml of blood from a vein in your arm, on two separate occasions, while you are attending 
hospital.  
After you leave hospital, we would like to know how you are getting on. One of our research team will 
therefore contact you every few months (up to 1 year from now) either by phone or letter, to ask you a few 
simple questions about your health. 
 
What do I have to do? 
 
You do not need to do anything. If you decide to take part, we will take a 10 ml blood sample during your 
current hospital attendance and on one more occasion and then contact you, as above, every 3 months, until 
1 year from now. No additional trips to hospital and no additional medication will be required. 
 
What are the side effects of taking part? 
 
The only risk is that of having a blood test. Like with any blood test, you may experience some minor 
discomfort, and there is a small risk of bruising or bleeding from the puncture site. 
 
What are the possible disadvantages and risks of taking part? 
 
The only risk is that of having a blood test. Like with any blood test, you may experience some minor 
discomfort, and there is a small risk of bruising or bleeding from the puncture site. 
 
Are there any benefits to me in taking part? 
 
There is no direct benefit to you for taking part. However, we hope the results of our research will further 
the medical profession’s understanding of why some patients have an increased tendency to form blood 
clots and this may lead to a better way to treat these patients. 
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What happens when the study stops? 
 
Once the research is completed and the results analysed, we will write you a letter explaining our findings 
in layman’s terms. You will continue to have medical follow up with your GP or hospital doctor as is 
necessary. 
 
What if something goes wrong? 
 
If you have any cause to complain about any aspect of the way you have been approached or treated during 
the course of this study the normal National Health Service complaints mechanisms are available to you 
and you are not compromised in any way because you have taken part in a research study. If you are 
harmed due to someone's negligence, then indemnity and/or compensation for negligence on the part of 
NHS staff will be provided by the East and North Hertfordshire NHS Trust.  
Formal complaints may be addressed to the Chief Executive, Lister Hospital, and Corey’s Mill Lane, 
Stevenage, SG1 4AB.Tel. No. 01438 781541 
 
Should you require independent advice about making a complaint or seeking compensation, you may wish 
to contact the Independent Complaints Advocacy service (ICAS) for Bedfordshire & Hertfordshire at 
Pohwer ICAS. Suite 19, The Pixmore Centre, Pixmore Avenue, Letchworth, Herts, SG6 1JG (Tel 0845 456 
1082).  
 
Will my taking part in this study be kept confidential? 
 
The results of this study will be kept strictly confidential, although we will inform your general practitioner 
of your participation in this research.  
 
What will happen to the results of the study? 
 
We hope that the results of the research as a whole will be published in a peer-reviewed scientific journal. 
This will not contain any patient-specific data  
 
Who is organising and funding the research? 
 
The research is organised by and funded by East and North Hertfordshire NHS Trust. 
 
Who has reviewed the study? 
 
The study has been reviewed and given a favourable ethical opinion by the Hertfordshire Research Ethics 
Committee. 
 
Contact for further information 
 
If you or your relatives wish to discuss any part of this research further, please contact the 
Cardiology Research Team on bleep 0235 or 0031 via Hospital Switch Board 01438-314333 or else 
contact Dr Gorog’s or Prof. Farrington’s secretaries via hospital switch board. 
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      Lister Hospital 
Corey’s Mill Lane 
Stevenage 
Herts SG1 4AB 
 
Tel: 01438 314333 
 
Queen Elizabeth II Hospoital 
Howlands 
Welwyn garden City 
Herts AL7 4HQ 
 
Tel: 01707 328111 
www.enherts-tr.nhs.uk 
CONSENT FORM 
 
Title of Project:  
 
Risk of thrombotic events in Chronic renal failure (CRF) patients on Renal replacement 
therapy (RRT) 
  
 
Name of Researcher:  Dr D A Gorog / Dr Ken Farrington 
Please initial box 
 
1. I confirm that I have read and understand the information sheet     
 for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to  
 Withdraw my consent at any time, without giving any reason and without  
 my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked  
 at by responsible individuals from the, sponsor (East & North Herts NHS 
             Trust) or from regulatory authorities (East & North Herts NHS Trust) 
             where it is relevant to my taking part in research. I give permission for these 
             individuals to have access to my records. 
 
4. I agree to take part in the above study.      
 
5. I agree for my GP to be informed of my participation in this study.   
 
            
Name of Patient    Date   Signature 
 
            
Study Number: REC Ref 09/H0311/25 
 
Centre Number: 
 
Patient Identification Number: 
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Name of person taking consent  Date              Signature 
(If different from researcher) 
 
            
Researcher    Date   Signature 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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STUDY NO.  statin  
Hosp. No  BB  
Initials  Folic acid  
DOB  Diuretics  
Gender  Alfa-calcidol  
Age  Iron  
Ethnicity  B12  
Contact No.  Phosp. Binder  
Cause of ESRF  Tinzaparin  
Medical History  Other Meds  
Co-Morbidity 1  Hb  
Co-Morbidity 2  WCC  
Co-Morbidity 3  Platelet  
Co-Morbidity 4  Na  
Diabetic  K  
HTN  Bicarb.  
Prior CAD  Urea  
CVA/TIA  Creatinine  
PVD  Ca  
Lupus/APAb  Phosphate  
Dialysis start   CRP  
Access History 
(incld. date/ site) 
 ALT  
TransplantHistory 
(incld.date/type) 
 KRU  
Previous  CV 
Intervention 
 Other bloods  
ASA  Dry Weight  
Clopidogrel  Pre HD Obs  
EPO / Dose  Post HD Obs.  
Insulin  GTT OT  
OHA  GTT LT  
ACE/ARB  Date/time Test  
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      Lister Hospital 
Coreys Mill Lane 
Stevenage 
Herts SG1 4AB 
 
Tel: 01438 314333 
 
Queen Elizabeth II Hospital 
Howlands 
Welwyn garden City 
Herts AL7 4HQ 
 
Tel: 01707 328111 
www.enherts-tr.nhs.uk 
REC Ref 09/H0311/25 
GP INFORMATION SHEET. 
 
Patient Name:………………………………………………… 
Patient DOB:…………………………………………………. 
Your patient participated in the research below and gave _ ml venous/fistula blood to be 
tested as part of the research study below, on ……….. (date) 
 
Study Title: Risk of thrombotic events in chronic renal failure (CRF) patients  
Patients with Chronic renal failure (CRF) despite being on optimal renal replacement 
therapy (RRT) remain at increased risk of acute thrombotic events. Patients with renal 
impairment have a high mortality from cardiovascular disease – such that a dialysis 
patient aged 30 has a relative risk of mortality over 100 times that of his peer without 
renal disease. The reason for this is unclear, but likely to be related to the increased 
platelet reactivity, impaired thrombolysis or both. There is currently no way to identify 
which patients are likely to have thrombotic event, and thus whom to target with more 
aggressive anti-platelet treatment. We propose to identify patients, through blood tests, 
who remain pro-thrombotic and/or have impaired fibrinolysis despite optimal treatment 
and observe whether this is related to an increase in acute thrombotic events. If these tests 
can identify which patients are at risk of further events, this group can be targeted to 
individualise and optimize the anti-platelet medication to achieve a more aggressive anti-
platelet effect, in order to reduce the risk of further thrombosis. 
The research involves taking a one-off blood sample, and telephone follow-up of patients. 
The research is been organised and funded by East and North Hertfordshire NHS Trust 
and the study has been approved by the Hertfordshire Research Ethics Committee. 
If you wish to discuss any part of this research further, please contact Cardiology 
Research Team at the QE2 hospital on 01707 328 111 and ask for bleep 0031/0235, Dr 
Diana Gorog, Consultant Cardiologist via her secretary on 01707 365 036 or Prof. Ken 
Farrington, Consultant Nephrologist via hospital switchboard 01438 314333. 
Version1.0 dated 01/02/2009
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